Obstructive Sleep Apnea

On this page

Quick Reference

RxDrug of choiceContinuous positive airway pressure (CPAP)

AltAlternativesMandibular advancement device, hypoglossal nerve stimulation, pharmacotherapy (solriamfetol, atomoxetine/oxybutynin, AD109, sulthiame, tirzepatide)

⊘AvoidBenzodiazepines (e.g., triazolam), prolong apnea and worsen hypoxemia; supplemental oxygen as monotherapy

DxTest of choiceIn-laboratory polysomnography (PSG)

ScKey scoreSTOP-Bang (score ≥3 high risk), Epworth Sleepiness Scale (>10 abnormal)

→When to referCPAP intolerance, residual symptoms despite adherence, consideration of HGNS or surgery, pediatric OSA with persistent disease after adenotonsillectomy, complex overlap syndromes

CPAP is first-line for moderate-severe OSA; adherence is critical for cardiovascular benefit. Alternative therapies exist for CPAP-intolerant patients. Weight loss and treatment of comorbidities are essential.

Obstructive sleep apnea (OSA) is a highly prevalent sleep disorder characterized by repetitive pharyngeal collapse, intermittent hypoxia, and sleep fragmentation. It affects an estimated 22.6% of adults with moderate-to-severe disease, yet most remain undiagnosed. Untreated OSA is independently associated with hypertension, cardiovascular disease, stroke, and cognitive decline. Diagnosis is confirmed by polysomnography (AHI ≥5 events/h), with severity stratified by AHI. First-line therapy is continuous positive airway pressure (CPAP), which improves symptoms and blood pressure; cardiovascular benefit is most pronounced in adherent patients. Alternative therapies include mandibular advancement devices, hypoglossal nerve stimulation, and emerging pharmacotherapy. Weight loss is a critical adjunct. Management requires a multidisciplinary approach with attention to adherence, comorbidities, and long-term surveillance.

Overview and Recommendations

Background

•Obstructive sleep apnea (OSA) is a sleep-related breathing disorder defined by repetitive pharyngeal collapse during sleep, causing intermittent hypoxia and sleep fragmentation. Diagnosis requires an apnea-hypopnea index (AHI) ≥5 events/h on polysomnography, with severity stratified as mild (5-14), moderate (15-29), and severe (≥30).
•OSA is highly prevalent: multinight monitoring estimates 22.6% of adults have moderate-to-severe disease (AHI >15), yet >90% remain undiagnosed. It is independently associated with hypertension, cardiovascular disease, stroke, and cognitive decline, with a dose-response relationship between hypoxic burden and adverse outcomes.
•Pathophysiology involves anatomical predisposition (obesity-related pharyngeal fat deposition, craniofacial restriction) and dynamic endotypic traits, collapsibility, loop gain, arousal threshold, and neuromuscular compensation. These endotypes predict response to oral appliances and hypoglossal nerve stimulation.
•Dominant risk factors: obesity (strongest modifiable), male sex, older age, menopause, family history, and craniofacial abnormalities. The STOP-Bang questionnaire (score ≥3) has 93% sensitivity for moderate-to-severe OSA and is the preferred screening tool.
•Untreated OSA carries significant prognostic stakes: hypoxic burden (area under desaturation curve) predicts incident CVD (HR 1.45 per SD), and overlap syndrome with COPD increases mortality (HR 1.74). CPAP reduces blood pressure and symptoms, but cardiovascular benefit is most evident in adherent patients with high pulse rate response to events.

Evaluation

•Suspect OSA in patients with habitual snoring, witnessed apneas, gasping/choking, or excessive daytime sleepiness (Epworth >10). However, up to 50% with moderate-severe OSA deny sleepiness; maintain high suspicion in obesity, hypertension, or CVD.
•Ask about nocturia, morning headache, dry mouth, impaired concentration. In women, atypical symptoms include insomnia, fatigue, mood disturbance. In children, look for snoring, mouth breathing, enuresis, behavioral issues.
•Examine for obesity (BMI ≥30), neck circumference >43 cm (men) or >38 cm (women), retrognathia, macroglossia, Mallampati class III/IV, tonsillar hypertrophy, and nasal obstruction. Check for right heart failure signs in advanced disease.
•Screen with STOP-Bang: score ≥3 warrants confirmatory testing. Sensitivity ~93% for moderate-severe OSA; specificity ~40%.
•Order in-laboratory polysomnography (PSG) as gold standard. AHI ≥5 confirms OSA. For high pretest probability patients without comorbidities, home sleep apnea testing (HSAT) is an alternative but may underestimate AHI.
•Consider split-night PSG if diagnostic portion shows AHI ≥15 and ≥3 hours remain for CPAP titration.
•Assess for comorbidities: check ABG if obesity hypoventilation suspected (serum bicarbonate ≥27 mmol/L is sensitive screen); obtain PFTs if overlap with COPD.
•Evaluate nocturnal hypoxemia: hypoxic burden and T90 (SpO₂ <90% time) predict cardiovascular risk better than AHI. T90 >4.7% predicts postoperative complications (OR 1.91).
•Red flags: severe hypoxemia (SpO₂ <80% for >10% sleep), hypercapnic respiratory failure (PaCO₂ >50), cor pulmonale, encephalopathy, high-risk occupations.
•Differential includes central sleep apnea, OHS, periodic limb movement disorder, insomnia, narcolepsy. PSG with EEG and leg EMG distinguishes.

Management

•Initiate CPAP as first-line for moderate-severe OSA (AHI ≥15) or symptomatic mild OSA. Use auto-CPAP or fixed pressure based on titration. Target AHI <5.
•Monitor adherence: aim ≥4 h/night on ≥70% nights. Use telemedicine, peer support, early follow-up to improve use. Peer interventions increased mean use from 3.7 to 4.5 h/night.
•For COMISA, treat insomnia with CBT-I before or concurrent with PAP.
•For CPAP intolerance, consider mandibular advancement device (MAD) for mild-moderate OSA. Meta-analysis: MAD reduces AHI by ~15.8 events/h vs sham, but CPAP is more effective.
•Hypoglossal nerve stimulation (HGNS) for moderate-severe OSA in CPAP-intolerant patients. STAR trial: 68% median AHI reduction at 12 months. Requires absence of concentric collapse on sleep endoscopy.
•Adenotonsillectomy is first-line for pediatric OSA. CHAT trial: 79% normalization vs 46% watchful waiting. Postoperative PSG needed if obese, severe baseline AHI, or asthma (40% residual risk).
•Bariatric surgery: 86.6% OSA remission at 5 years. Perioperative risk increased (OR 4.3), so optimize CPAP preoperatively.
•Pharmacotherapy for residual sleepiness after PAP: solriamfetol 37.5-150 mg daily (improves MWT by 11.2 min). Emerging options: atomoxetine 80 mg + oxybutynin 5 mg (AHI reduction 63%), AD109 2.5/75 mg (44.1% reduction), sulthiame 400 mg (41% reduction, but paresthesia), tirzepatide 10-15 mg weekly (20-25 events/h reduction with weight loss).
•Weight loss is critical adjunct: 5-10% weight loss significantly reduces AHI. CPAP plus weight loss reduces systolic BP more than either alone.
•Positional therapy for supine-predominant OSA (supine:non-supine AHI ratio ≥4:1, non-supine AHI <10). Use wearable vibratory devices.
•Oropharyngeal exercises: 30 min daily for 3 months reduced AHI from 22.4 to 13.7 events/h.
•In acute hypercapnic respiratory failure with OHS and severe OSA, start CPAP immediately. If fails, use NIV. Target SpO₂ 88-92%. In ADHF with OSA, in-hospital CPAP improved LVEF by 4.5%.
•Avoid: supplemental oxygen alone (no BP benefit), flexible pressure delivery (no adherence benefit), benzodiazepines (prolong apnea), and long-term NIV without reassessment.
•Monitor annually: adherence data, symptom review, repeat PSG if weight change >10% or symptoms recur. Screen for hypertension, atrial fibrillation, glaucoma.
•Refer to sleep specialist for CPAP intolerance, residual symptoms, HGNS/surgery consideration, pediatric persistent OSA, complex overlap syndromes.

Board Review — High Yield

•STOP-Bang score ≥3, 93% sensitivity for moderate-to-severe OSA; use as first screen.
•AHI ≥5 events/h, diagnostic threshold for OSA on polysomnography.
•CPAP reduces 24-hour mean arterial pressure by ~2.4 mm Hg, HeartBEAT trial.
•Hypoxic burden, area under desaturation curve; predicts CVD better than AHI (HR 1.45 per SD).
•T90 >4.7%, predicts postoperative cardiorespiratory complications (OR 1.91).
•Adenotonsillectomy normalizes PSG in 79% of children, CHAT trial; residual disease common if obese.
•Atomoxetine 80 mg + oxybutynin 5 mg, reduces AHI by 63% in single-night study.
•Untreated overlap syndrome (COPD+OSA), increases all-cause mortality (HR 1.74).

Deep Dive — Evidence Details

1. Definition, Classification and Nomenclature

▸OSA is defined by the apnea-hypopnea index (AHI) with severity thresholds of 5, 15, and 30 events/h.
▸The condition is heterogeneous, with positional and REM-related subtypes that influence treatment selection.
▸Screening with STOP-Bang (score ≥3) identifies >90% of patients with moderate to severe OSA.

HY High Yield: The STOP-Bang questionnaire (Snoring, Tiredness, Observed apnea, high BP, BMI>35, Age>50, Neck circumference>40 cm, male gender) is a validated screening tool: a score ≥3 has 93% sensitivity for moderate-severe OSA and 100% for severe OSA [14].

Obstructive sleep apnea (OSA) is a sleep-related breathing disorder characterized by repetitive partial or complete collapse of the pharyngeal airway during sleep, resulting in intermittent hypoxia, recurrent arousals, and sleep fragmentation. The condition is defined by the apnea-hypopnea index (AHI), the number of apneas and hypopneas per hour of sleep. An apnea is a ≥90% reduction in airflow for ≥10 seconds; a hypopnea is a ≥30% reduction in airflow accompanied by ≥3% oxygen desaturation or an arousal. The diagnostic threshold for OSA is an AHI ≥5 events/h, with severity stratified by the AHI: mild (5-14), moderate (15-29), and severe (≥30). This classification, endorsed by the American Academy of Sleep Medicine, forms the basis for treatment decisions and prognostication ^[2]^A1c^[4]^A1c^[7]^A1c.

Also Called / Synonyms

Obstructive sleep apnea-hypopnea syndrome (OSAHS)
Sleep apnea syndrome
Upper airway resistance syndrome (historical, now considered part of the OSA spectrum)
Pediatric OSA (when diagnosed in children)

Classification of Types and Variants

OSA is a heterogeneous disorder with several defined subtypes based on polysomnographic patterns and clinical phenotypes. Positional OSA (supine-predominant) is defined by a supine AHI to non-supine AHI ratio ≥4:1 with a non-supine AHI <10 events/h; this phenotype is highly repeatable from night to night, particularly in males ^[8]^C4. REM-related OSA is characterized by respiratory events predominantly during rapid eye movement sleep. Other emerging endotype-based classifications include categories based on pharyngeal collapsibility, loop gain, and arousal threshold, which predict response to oral appliance therapy ^[9]^C4 and cardiovascular treatment benefit ^[10]^B2b.

Severity Classification

Severity	AHI (events/h)	Typical Clinical Context
Mild	5-14	May be asymptomatic; often treated if symptoms or comorbidities present
Moderate	15-29	Commonly symptomatic; treatment recommended
Severe	≥30	High risk of cardiovascular and neurocognitive consequences; treatment strongly indicated

Clinical Significance

OSA is a highly prevalent condition. Multinight home monitoring studies estimate that approximately 22.6% of adults have moderate to severe OSA (AHI >15) ^[12]^C4. Clinically diagnosed OSA prevalence has risen dramatically, from 0.14% to 4.59% in a Canadian province over 2003-2020, reflecting increased recognition ^[31]^B2c. Untreated OSA is independently associated with , cardiovascular disease, stroke, cognitive decline, and increased healthcare utilization, with a dose-response relationship between positive airway pressure use and reduced hospitalizations ^[28]^B2b. Screening tools such as the STOP-Bang questionnaire (score ≥3) have high sensitivity (93%) for detecting moderate to severe OSA and should be employed in at-risk populations ^[14]^D5.

Pearl: Use the STOP-Bang questionnaire as a pragmatic first screen in all patients with hypertension, obesity, or daytime sleepiness; a score ≥3 warrants confirmatory testing with or home sleep apnea testing ^[14]^D5.

3. Epidemiology, Etiology and Risk Factors

▸Moderate-to-severe OSA (AHI >15) affects approximately 22.6% of the global population, with over 90% undiagnosed.
▸Obesity is the strongest modifiable risk factor, operating through distinct anatomic pathways in lean vs. obese patients.
▸Comorbid conditions (COPD, asthma, connective tissue disorders, cleft palate) substantially increase OSA risk and alter outcomes.

HY High Yield: The STOP-Bang questionnaire is a pragmatic screening tool: score ≥3 yields 93% sensitivity for moderate-to-severe OSA; high-risk scores (5-8) warrant definitive sleep testing [14].

From the mechanisms of pharyngeal collapse and ventilatory instability, the clinical burden of OSA emerges as a common and frequently undiagnosed condition. Multinight home monitoring in a large global community sample using a validated under-mattress sensor estimated a prevalence of moderate-to-severe OSA (AHI >15 events/h) of 22.6% (95% CI, 20.9-24.3%) ^[12]^C4. Over 90% of cases remain undiagnosed ^[94]^B2a, underscoring the gap between population burden and clinical recognition.

Demographic and temporal patterns

Men are affected more than women, and prevalence rises with age ^[83]^D5. Premenopausal women are relatively protected; after , OSA prevalence increases sharply ^[83]^D5. The condition aggregates in families, an association not fully explained by shared obesity ^[83]^D5. Temporal trends show a rising prevalence, driven largely by the global obesity epidemic ^[83]^D5.

Risk factors

Obesity is the dominant modifiable risk factor. In a cross-sectional MRI study of 583 patients with moderate-to-severe OSA, higher BMI was associated with larger pharyngeal soft-tissue volumes (tongue, soft palate, lateral walls) and altered airway shape, a smaller retropalatal lateral dimension and larger anteroposterior distances ^[104]^C4. Lean patients with OSA had smaller craniofacial measures and more retrognathia, indicating different anatomic pathways to pharyngeal collapse ^[104]^C4.

Other established risk factors include male sex, older age, menopause, family history, craniofacial abnormalities (e.g., retrognathia, cleft palate), adenotonsillar hypertrophy (especially in children), and conditions that narrow the upper airway or alter ventilatory control. The STOP-Bang questionnaire (snoring, tiredness, observed apnea, blood pressure, BMI, age, neck circumference, male gender) provides a practical risk-stratification tool: a score ≥3 has 93% sensitivity for moderate-to-severe OSA and a negative predictive value of 90% ^[14]^D5.

Risk Factor	Strength of Association	Evidence Level
Obesity (especially higher BMI)	Strong	2b ^[104]^C4, 5 ^[83]^D5
Male sex	Strong	5 ^[83]^D5
Older age	Strong	5 ^[83]^D5
Postmenopausal status	Strong	5 ^[83]^D5
Family history	Moderate	5 ^[83]^D5
Craniofacial/airway abnormalities (retrognathia, cleft palate)	Strong	4 ^[104]^C4, 2a ^[93]^B2a
Adenotonsillar hypertrophy (children)	Strong	1a ^[96]^A1a
(overlap syndrome)	Moderate (32% prevalence in COPD)	2b ^[101]^B2b
Asthma	Moderate	5 ^[43]^D5
Hypermobile Ehlers-Danlos syndrome / Hypermobility Spectrum Disorder	Moderate	3b ^[107]^B3b
Hypothyroidism,	Moderate	5 ^[83]^D5
Smoking, alcohol use	Weak-moderate	5 ^[83]^D5

Special populations

In patients with COPD, the prevalence of OSA (overlap syndrome) is 32%, and untreated OVS is associated with increased all-cause mortality (HR 1.74; 95% CI, 1.03-2.94) ^[101]^B2b. Among children with cleft lip and/or palate, the prevalence of sleep-disordered breathing is 16% (95% CI, 12-21%) ^[93]^B2a. Comorbid insomnia and sleep apnea (COMISA) affects 3.1% of the general population and 14.5% of those with OSA, and carries an independent risk for uncontrolled (OR 1.88; 95% CI, 1.23-2.89) ^[105]^C4.

These epidemiologic patterns and risk factor profiles shape the pretest probability of OSA in clinical encounters and guide targeted screening efforts. The clinical presentation that follows, daytime sleepiness, witnessed apneas, and nocturnal symptoms, emerges from this population backdrop.

Pearl: Comorbid conditions (COPD, asthma, connective tissue disorders, cleft palate) substantially increase OSA risk and alter outcomes.

4. Clinical Presentation

▸The classic triad of snoring, witnessed apneas, and excessive daytime sleepiness is present in a minority; many patients present with fatigue, insomnia, or cognitive complaints.
▸Physical examination should include neck circumference, Mallampati score, and tonsillar grading; obesity and craniofacial abnormalities are key risk factors.
▸Atypical presentations are common in women, children, and the elderly, and racial disparities in disease severity and referral patterns exist.

HY High Yield: The STOP-Bang questionnaire (Snoring, Tiredness, Observed apnea, Pressure [hypertension], BMI >35, Age >50, Neck circumference >40 cm, male gender) is a validated screening tool: score ≥3 has 93% sensitivity for moderate-to-severe OSA [14].

The clinical presentation of OSA reflects the interplay of upper airway collapse during sleep and its downstream consequences on sleep architecture, gas exchange, and autonomic function. Symptoms arise from both the nocturnal respiratory events and the resulting sleep fragmentation, and their recognition is essential for timely diagnosis.

Presenting Symptoms

The classic triad includes snoring, witnessed apneas, and excessive daytime sleepiness (EDS). Snoring is nearly universal but not specific; the partner's report of breathing pauses, gasping, or choking is more predictive. Daytime sleepiness is quantified by the Epworth Sleepiness Scale (ESS), with a score >10 indicating abnormal sleepiness. However, up to 50% of patients with moderate-to-severe OSA (apnea-hypopnea index [AHI] >15) do not report EDS, particularly those without overt cardiovascular disease ^[118]^A1b. Other common symptoms include morning headache (due to nocturnal hypercapnia), nocturia (from atrial natriuretic peptide release), dry mouth on awakening, and impaired concentration or memory. Fatigue, mood disturbance, and decreased libido are also frequent ^[50]^D5.

Physical Examination Findings

Examination focuses on identifying risk factors and upper airway abnormalities. Key findings include:

Obesity (BMI ≥30 kg/m²) and increased neck circumference (>43 cm in men, >38 cm in women) ^[50]^D5.
Craniofacial features: retrognathia, micrognathia, high-arched palate, macroglossia.
Oropharyngeal crowding: Mallampati class III or IV, enlarged tonsils (grade III-IV), elongated uvula, and redundant pharyngeal mucosa.
Nasal obstruction: deviated septum, turbinate hypertrophy, polyps.
(often resistant) and signs of right heart failure (e.g., pedal edema, elevated jugular venous pressure) in advanced cases.

Phenotypic Variants

OSA is heterogeneous. The STOP-Bang questionnaire stratifies risk: a score ≥3 has 93% sensitivity for moderate-to-severe OSA (AHI >15) and 100% sensitivity for severe OSA (AHI >30) ^[14]^D5. Variants include:

Nonsleepy OSA: patients with AHI >15 but ESS <10; cardiovascular risk remains elevated, but CPAP trials show inconsistent blood pressure benefit ^[128]^A1a.
(OHS): OSA plus awake hypercapnia (PaCO₂ >45 mm Hg), often with . CPAP and noninvasive ventilation are similarly effective ^[37]^A1a^[115]^A1b.
Overlap syndrome: plus OSA, with greater hypoxemia and pulmonary hypertension risk ^[103]^D5.
Pediatric OSA: presents with snoring, mouth breathing, nocturnal , and behavioral problems (ADHD-like symptoms) rather than sleepiness ^[126]^C4^[127]^B2b.

Red Flags

Certain features warrant urgent evaluation:

Severe nocturnal hypoxemia (SpO₂ <80% for >10% of sleep time).
Hypercapnic respiratory failure (awake PaCO₂ >50 mm Hg).
Cor pulmonale (right heart failure from chronic hypoxemia).
Acute-on-chronic hypercapnic encephalopathy (confusion, asterixis).
High-risk occupations (commercial drivers, pilots) where untreated sleepiness poses public safety risk.

Atypical Presentations

Women often report insomnia, fatigue, morning headaches, and mood disturbance rather than classic sleepiness, leading to underdiagnosis ^[114]^A1b. Black men present with more severe disease (mean AHI 52.4 vs. 39.0 in White men) and higher ESS scores, yet are less likely to be referred for sleep studies ^[130]^B2b. In the elderly, OSA may manifest as cognitive decline, nocturnal confusion, or falls. Children with mild sleep-disordered breathing may have symptom persistence (57% at 1 year) despite stable AHI ^[127]^B2b.

Pearl: The absence of daytime sleepiness does not rule out clinically significant OSA; objective testing is indicated when the STOP-Bang score is ≥3 or when witnessed apneas are reported, regardless of ESS.

Common Presenting Symptoms of OSA

Symptom	Frequency	Clinical Significance
Snoring	>90%	Sensitive but not specific; partner report of pauses is more predictive
Witnessed apneas	50-70%	Strongly associated with moderate-to-severe OSA
Excessive daytime sleepiness	40-60%	Quantified by Epworth Sleepiness Scale (ESS >10 abnormal)
Morning headache	10-30%	Suggests nocturnal hypercapnia
Nocturia	30-50%	Due to atrial natriuretic peptide release from negative intrathoracic pressure
Impaired concentration/memory	30-50%	Related to sleep fragmentation
Fatigue/mood disturbance	40-60%	Often the chief complaint in women

Data from ^[50]^D5^[114]^A1b^[130]^B2b

5. Diagnosis and Workup

▸Attended in-laboratory polysomnography remains the gold standard for OSA diagnosis, with an AHI ≥5 events/h as the diagnostic threshold.
▸Home sleep apnea testing is a valid alternative for patients with high pretest probability and no significant cardiopulmonary comorbidities, but it underestimates AHI and has a higher failure rate.
▸Night-to-night variability in OSA severity is substantial, and single-night studies may misclassify up to 20-50% of patients, highlighting the need for clinical correlation and, when appropriate, repeat testing.

Dx Diagnostic Essentials: The gold-standard diagnostic test for obstructive sleep apnea is **attended in-laboratory polysomnography** with calculation of the apnea-hypopnea index (AHI). An AHI ≥5 events/h is diagnostic [50].

HY High Yield: A serum bicarbonate level <27 mmol/L in an obese patient with sleep-disordered breathing has a high negative predictive value for excluding obesity hypoventilation syndrome, reducing the need for urgent arterial blood gas measurement [1].

The clinical suspicion raised by symptoms and signs must be confirmed by objective testing, with attended in-laboratory (PSG) as the gold standard ^[50]^D5. PSG records EEG, electrooculography, chin and leg electromyography, airflow, respiratory effort, oxygen saturation, and body position, allowing calculation of the apnea-hypopnea index (AHI), the number of apneas and hypopneas per hour of sleep. An AHI ≥5 events/h establishes the diagnosis, with severity classified as mild (5-14.9), moderate (15-29.9), or severe (≥30) ^[50]^D5.

Home Sleep Apnea Testing (HSAT)

For selected outpatients with a high pretest probability of moderate-to-severe OSA and no significant comorbidities, home sleep apnea testing (HSAT) using a portable monitor (type 3 device, typically recording airflow, respiratory effort, and oximetry) is an acceptable alternative to PSG ^[151]^D5. HSAT reduces cost and wait times, but has a higher failure rate (up to 20% in some series) and underestimates AHI compared to PSG, particularly in milder disease ^[151]^D5^[156]^D5. In a randomized trial, 4-week outcomes of CPAP adherence and symptom improvement were equivalent between a home-based protocol (level 3 test + auto-CPAP) and in-laboratory PSG ^[139]^A1b. The American Academy of Sleep Medicine endorses HSAT only when used as part of a comprehensive sleep evaluation, not for screening asymptomatic patients ^[151]^D5.

Split-Night Polysomnography

To expedite both diagnosis and treatment initiation, split-night PSG combines a diagnostic portion (≥2 hours of sleep) with CPAP titration in the same night. This approach is appropriate when the AHI during the diagnostic portion is ≥15 events/h and at least 3 hours remain for titration ^[150]^D5. Split-night studies are cost- and time-efficient but may be less accurate than full-night PSG for patients with mild or positional OSA ^[150]^D5.

Night-to-Night Variability and Multinight Monitoring

Single-night studies may misclassify OSA severity because of significant night-to-night variability. In a large community-based study of over 67,000 individuals monitored for ~170 nights using an under-mattress sensor, the likelihood of misdiagnosis based on a single night ranged from 20% to 50% ^[12]^C4. Misclassification error decreased with more monitoring nights, stabilizing after 14 nights (F1-score 0.94 vs. 0.77 for 1 night) ^[12]^C4. Multinight monitoring is not yet standard but may improve diagnostic accuracy, especially for patients with borderline or positional OSA.

Screening Tools

The STOP-Bang questionnaire (Snoring, Tiredness, Observed apnea, high blood Pressure, BMI >35 kg/m², Age >50, Neck circumference >40 cm, male Gender) is the most validated screening tool. A score ≥3 identifies high risk for OSA, with a sensitivity of approximately 90% for moderate-to-severe disease ^[130]^B2b^[131]^B2b. However, specificity is modest (around 40%), so a positive screen mandates confirmatory testing. The Epworth Sleepiness Scale (ESS) measures subjective daytime sleepiness (score >10 indicates pathological sleepiness, minimum clinically important difference 2 units) but is not diagnostic for OSA ^[142]^A1a.

Biomarkers

No single biomarker has sufficient diagnostic accuracy for clinical use. C-reactive protein, fasting glucose, and lipid profiles are elevated in OSA but lack specificity ^[152]^D5. Hypoxic burden (area under the desaturation curve per event) has been associated with incident cardiovascular disease (adjusted HR 1.45 in MESA, 1.13 in MrOS) and may eventually refine risk stratification, but it is not yet part of routine diagnostic criteria ^[81]^B2b.

Test	Indication	Advantages	Limitations
In-laboratory PSG	Gold standard; all patients with suspected OSA, especially with comorbidities	Comprehensive; accurate AHI and sleep staging	Expensive; limited availability; single-night snapshot
HSAT (type 3)	High pretest probability of moderate-to-severe OSA; no significant cardiopulmonary disease	Convenient; lower cost; home setting	Underestimates AHI; higher failure rate; cannot exclude mild OSA
Split-night PSG	AHI ≥15 on diagnostic portion with adequate time for titration	Combines diagnosis and treatment in one night	Potential for incomplete titration; not for mild OSA
MST (type 4, e.g., oximetry)	Limited screening; not recommended alone for diagnosis	Simple; widely available	High false-negative rate; no measure of ventilation or arousal

Diagnostic Algorithm

Clinical suspicion: Based on symptoms (snoring, witnessed apneas, daytime sleepiness, nocturia, morning headache) and risk factors (obesity, male sex, age, family history, craniofacial abnormalities).
Pretest probability assessment: Use STOP-Bang or other validated tool. High probability (≥3) → proceed to testing. Low probability → consider alternative diagnoses.
Confirmatory testing:
- Preferred: In-laboratory PSG. If PSG is unavailable or patient cannot attend, consider HSAT in appropriate candidates.
- Alternative: Split-night PSG if AHI ≥15 on initial diagnostic portion.
Severity classification: Based on AHI (mild 5-14.9, moderate 15-29.9, severe ≥30) and oxygen desaturation nadir.
Consider additional testing: If is suspected, check arterial blood gas (serum bicarbonate ≥27 mmol/L is a sensitive screen) ^[1]^A1c. If overlap syndrome ( + OSA) is considered, obtain (spirometry, lung volumes, DLCO) ^[46]^A1c.

Pearl: A single-night PSG misclassifies severity in 20-50% of patients; when clinical suspicion is high but initial testing is negative, consider repeat or multinight monitoring ^[12]^C4.

6. Severity, Staging and Risk Stratification

▸AHI remains the standard severity classification, but hypoxic burden and T90 better predict cardiovascular outcomes and postoperative complications.
▸Polysomnographic endotypes (collapsibility, loop gain, arousal threshold, compensation) identify patients most likely to benefit from targeted pharmacotherapy.
▸Comorbid conditions (COPD overlap, COMISA, elevated NLRP3) dramatically amplify the prognostic significance of OSA and should prompt aggressive risk reduction.

HY High Yield: A T90 >4.7% of sleep time is the strongest independent PSG predictor of postoperative cardiorespiratory complications, exceeding AHI in multivariable models [175].

Given a polysomnographic diagnosis of OSA, the next step is to translate the raw data into a severity grade that drives therapy decisions and prognostication. The apnea-hypopnea index (AHI) remains the historical cornerstone: mild (5-14.9 events/h), moderate (15-29.9 events/h), and severe (≥30 events/h) ^[14]^D5. However, AHI alone omits key physiologic dimensions that better predict cardiovascular harm ^[22]^B2b^[81]^B2b.

Hypoxic Burden and Nocturnal Hypoxemia

AHI does not capture the depth or duration of oxygen desaturation. The hypoxic burden (HB), the total area under the respiratory event-related desaturation curve, adds independent prognostic value. In the Multi-Ethnic Study of Atherosclerosis (MESA), each 1‑SD increase in HB was associated with a 45% higher risk of incident cardiovascular disease (HR 1.45, 95% CI 1.14-1.84) ^[81]^B2b. The ventilatory burden (event‑related area under the ventilation signal) explained 78% of HB variation, whereas adiposity contributed <2% ^[81]^B2b. In a clinical cohort of 5,358 patients, HB and sleep time with SpO₂ <90% (T90), but not symptom subtypes, predicted major adverse cardiovascular events (MACE) over 78 months (HR 1.21 and 1.34, respectively) ^[82]^B2b.

T90 is a particularly actionable metric for perioperative risk: >4.7% of sleep time with SpO₂ <90% independently predicted cardiorespiratory complications or death within 30 days of surgery (OR 1.91) ^[175]^B2b. The oxygen desaturation index (ODI) has shown the most consistent association with ambulatory blood pressure elevation across studies ^[176]^D5.

Endotypic Traits

Beyond static thresholds, four endotypic traits derived from routine PSG signals refine risk: collapsibility (Vpassive), loop gain, arousal threshold, and compensation ^[179]^B2b. A higher arousal threshold predicts more severe hypoxic burden but shows a nonlinear, inverse U‑shaped relationship with AHI ^[179]^B2b. Patients with a low arousal threshold (<173.5% eupnea) have better upper airway patency, whereas those with a high arousal threshold combined with high compensation (reflecting very low Vpassive) have elevated NREM AHI ^[179]^B2b. These traits may guide pharmacologic targeting (e.g., atomoxetine-oxybutynin in low arousal threshold/ poor muscle responsiveness) ^[168]^A1b^[170]^A1b.

Comorbidity‑Anchored Risk Stratification

OSA rarely exists in isolation; its prognostic weight is amplified by coexisting conditions:

Condition	Risk (vs. OSA alone)	Source

Polysomnographic Phenotypes

Unsupervised clustering of PSG features identifies seven phenotypes, three of which, ‘periodic limb movements’, ‘hypopnoea and hypoxia’, and ‘combined severe’, carry 2‑fold higher cardiovascular risk that is missed by AHI severity categories alone ^[22]^B2b.

Controversies and Guideline Disagreement

Question	Position A (Traditional)	Position B (Evolving)	Strength
Primary metric for prognosis	AHI severity categories	Hypoxic burden / T90	Moderate; HB is not yet incorporated into all guidelines
Role of arousal threshold	Not routinely assessed	Identifies drug‑responsive endotypes	Low; requires validation in outcome trials

Pearl: For cardiovascular risk stratification, the hypoxic burden (area under the desaturation curve) is more informative than AHI alone; a T90 >4.7% of sleep time independently predicts postoperative cardiorespiratory complications ^[175]^B2b^[81]^B2b.

Severity Classification Metrics in Obstructive Sleep Apnea

Metric	Definition	Severity Thresholds	Prognostic Significance
AHI	Apneas + hypopneas per hour of sleep	Mild 5-14.9, Moderate 15-29.9, Severe ≥30	Standard; correlates with symptoms and cardiovascular risk but lacks granularity ^[14]^D5
Hypoxic burden (HB)	Area under the event‑related desaturation curve (per‑event)	No established cutoffs; continuous risk increase	1‑SD increase → HR 1.45 for incident CVD (MESA) ^[81]^B2b
T90	% of sleep time with SpO₂ <90%	>4.7% identifies high postoperative risk	OR 1.91 for 30‑day cardiorespiratory complications ^[175]^B2b
ODI (oxygen desaturation index)	Desaturations ≥3% per hour	≥15/h considered moderate-severe	Most consistent association with ambulatory BP elevation ^[176]^D5
Arousal threshold	Epiglottic pressure swings triggering arousal	<173.5% eupnea (low)	Predicts hypoxic burden; nonlinear relation to AHI ^[179]^B2b

Comorbidity‑Anchored Risk Amplifiers

Condition	Risk Estimate (vs. OSA alone)	95% CI	Reference
COPD‑OSA overlap (untreated)	All‑cause mortality HR 1.74	1.03-2.94	^[101]^B2b
COMISA (insomnia + OSA)	Uncontrolled hypertension OR 1.88	1.23-2.89	^[105]^C4
Elevated NLRP3 (per 1‑SD)	Prevalent CKD OR 1.49	1.16-1.92	^[178]^B2b
OSA in young adults	Moderate/severe pain aOR 1.09	1.08-1.11	^[29]^C4

7. Acute Management and Exacerbation Rescue

▸Acute management of OSA focuses on three scenarios: hypercapnic respiratory failure (OHS/OVS), acute decompensated heart failure, and perioperative respiratory compromise.
▸CPAP is the first-line ventilatory support for acute exacerbations with severe OSA, including in OHS and ADHF, with a 4.5% LVEF improvement demonstrated in heart failure.
▸Postoperative risk is highest in patients with age >65, BMI ≥35, cardiothoracic surgery, and T90 >4.7%; these patients require enhanced monitoring.

Rx Drug of Choice: CPAP is the management of choice for acute exacerbations of OSA with hypercapnia or ADHF, at a pressure determined by auto-titration or fixed based on prior titration.

From the risk stratification established in the preceding section, the clinician must now identify which patients require urgent intervention. Acute of OSA targets three scenarios: acute-on-chronic hypercapnic respiratory failure (most often in [OHS]), acute decompensated heart failure (ADHF) with OSA, and perioperative respiratory compromise. The following pathway provides a time-critical approach.

Step 1: Initial Assessment and Severity Classification

When a patient with known or suspected OSA presents with dyspnea, altered mental status, or hypoxemia, obtain an arterial blood gas immediately. Measure serum bicarbonate: a value <27 mmol/L effectively excludes OHS when clinical suspicion is low (<20%), but when suspicion is high, proceed directly to ABG regardless of bicarbonate ^[1]^A1c (conditional recommendation, very low quality evidence).

Classify the acute presentation into one of three phenotypes:

Hypercapnic respiratory failure (PaCO₂ >45 mm Hg, pH <7.35) - suggestive of OHS or -OSA overlap (OVS)
Acute decompensated heart failure (clinical signs of congestion, elevated BNP, with known OSA)
Perioperative respiratory compromise (post-extubation stridor, oxygen desaturation, hypercapnia)

In patients with COPD, the presence of untreated OVS (OSA plus COPD) carries a markedly increased risk of death compared with COPD alone (hazard ratio, 1.74; 95% CI, 1.03-2.94) ^[101]^B2b (2b). Similarly, patients with OSA hospitalized for ADHF who are not treated have no improvement in left ventricular ejection fraction, whereas those started on CPAP improve by 4.5% (SE, 1.7%) over 3 nights ^[183]^A1b (1b).

Step 2: Oxygen and Ventilatory Support

Supplemental oxygen: Target SpO₂ 88-92% in patients at risk of hypercapnia. Avoid high-flow oxygen that may suppress hypoxic drive. In patients without hypercapnia, target SpO₂ ≥94%.

Positive airway pressure (PAP) is the management of choice. The decision tree is shown in Figure 1.

Figure 1: Acute management algorithm for OSA exacerbation. Adapted from ATS 2019 OHS guideline ^[1]^A1c and Khayat et al. 2009 ^[183]^A1b.

CPAP: For stable ambulatory patients with OHS and coexistent severe OSA, the ATS guideline recommends CPAP rather than NIV as first-line (conditional recommendation, very low quality) ^[1]^A1c. In the ADHF setting, immediate in-hospital CPAP (auto-adjusting or fixed pressure) improved LVEF by 4.5% (SE 1.7%) vs. -0.3% (SE 1.5%) in controls (p=0.03) ^[183]^A1b (1b).

NIV (bilevel positive airway pressure): Reserve for patients with OHS who fail CPAP (persistent hypercapnia, nocturnal desaturation) or those without severe OSA. For hospitalized patients with respiratory failure suspected of OHS, discharge with NIV until outpatient sleep study and PAP titration can be completed (ideally within 2-3 months) ^[1]^A1c (conditional recommendation).

Step 3: Pharmacologic Adjuncts

No drug is approved for acute OSA exacerbation. However, in patients with residual excessive daytime sleepiness after PAP optimization, solriamfetol (37.5-150 mg/d) improves wakefulness regardless of adherence to primary OSA therapy ^[184]^A1b (1b). This is not an acute rescue agent but may be considered during the transition to long-term care.

Step 4: Monitoring and Titration

In the acute setting, monitor SpO₂ continuously, end-tidal CO₂ if available, and check ABG after 1-2 hours of PAP therapy. For patients with OHS, a target PaCO₂ normalization is recommended ^[3]^A1c (conditional recommendation, low certainty).

For postoperative patients, the strongest predictors of cardiorespiratory complications within 30 days are: age >65 years, BMI ≥35 kg/m², cardiothoracic procedure, known cardiorespiratory risk factor, and T90 >4.7% (percentage of sleep time with SpO₂ <90%) ^[175]^B2b (2b). These patients should be monitored in a step-down or ICU setting with continuous oximetry and, if possible, .

Step 5: Transition to Long-term Management

Once the acute episode resolves, arrange for definitive outpatient sleep testing and PAP titration. For patients with OHS discharged on NIV, schedule a polysomnogram within 2-3 months to confirm optimal settings ^[1]^A1c. For all others, refer for long-term management as described in Section 8.

Drug / Modality Comparison Table

Modality	Indication	Key evidence	Acute setting use
CPAP	First-line for acute hypercapnia with severe OSA; ADHF with OSA	Improves LVEF by 4.5% in ADHF ^[183]^A1b; reduces AHI by 63% in one night ^[168]^A1b	First-line in hospital
NIV (bilevel)	Hypercapnic respiratory failure with OHS without severe OSA; CPAP failure	ATS guideline: conditional recommendation ^[1]^A1c	Second-line; also for discharge
Supplemental oxygen	Mild hypoxemia without hypercapnia; perioperative	Target SpO₂ 88-92% (hypercapnia risk)	Adjunctive, not primary
Solriamfetol	Residual daytime sleepiness after PAP	Improves MWT and ESS ^[184]^A1b	Outpatient only, not acute

Pearl: For any patient with acute hypercapnic respiratory failure and obesity without an alternative cause, start CPAP immediately if severe OSA is suspected; in-hospital CPAP in ADHF improves LVEF by 4.5% within 3 days, and untreated OVS carries a nearly doubled mortality risk (HR 1.74).

8. Long-term and Definitive Management

▸CPAP is first-line for moderate-to-severe and symptomatic mild OSA; adherence ≥4 h/night is a critical determinant of cardiovascular benefit [75,76].
▸Alternative therapies (mandibular advancement devices, hypoglossal nerve stimulation, bariatric surgery) are effective for CPAP-intolerant or non-adherent patients [182,210,92].
▸Emerging pharmacotherapy (AD109, tirzepatide, sulthiame) shows significant AHI reduction but is not yet first-line [170,77,110].

HY High Yield: CPAP adherence ≥4 h/night is associated with improved cardiovascular outcomes in secondary analyses of RICCADSA [75].

! Warning: Do not rely on flexible pressure delivery modes (C-Flex, etc.) to improve adherence; meta-analysis shows no benefit [120].

After acute stabilization, the focus shifts to long-term therapy aimed at eliminating apneic events, normalizing oxygenation, and reducing cardiovascular risk. is guided by OSA severity, symptoms, patient preference, and comorbidities.

Step 1: Selecting First-Line Therapy

For patients with moderate-to-severe OSA (AHI ≥15 events/h) or symptomatic mild OSA (AHI 5-14 with daytime sleepiness, , or cardiovascular disease), is first-line therapy ^[206]^A1c. For mild OSA without symptoms, watchful waiting or conservative measures (positional therapy, weight loss) may be appropriate ^[127]^B2b.

Step 2: Initiating and Optimizing PAP

CPAP can be initiated with auto-titration or in-lab titration; home-based diagnosis and treatment yields equivalent outcomes to lab-based ^[139]^A1b^[198]^B2b. Objective adherence monitoring is essential. Telemedicine interventions, peer support, and early proactive follow-up improve adherence: mean CPAP use 4.5 vs 3.7 h/night with peer-driven intervention ^[195]^A1b; telemedicine noninferior to monthly visits for long-term adherence ^[203]^A1b; proactive telemedicine increased adherence by 0.2 h/night and reduced mask leakage ^[204]^A1b. In patients with COMISA (comorbid insomnia and OSA), CBT-I followed by PAP improves sleepiness more than PAP alone ^[212]^A1a.

Treatment failure: If AHI remains >15 on optimal PAP or adherence <4 h/night, escalate to alternative therapies.

Step 3: Alternative and Adjunctive Therapies

s are recommended for mild-to-moderate OSA or CPAP-intolerant severe OSA. Meta-analysis (8 RCTs, 642 participants) showed MADs reduced AHI vs sham by -15.8 events/h (95% CI -23.1 to -8.4), but CPAP produced greater AHI reduction (MD 11.8 events/h higher residual AHI; 95% CI 6.6-17.0) ^[210]^A1a.

is effective for moderate-severe OSA in CPAP-intolerant patients. The STAR trial reported 68% median AHI reduction (from 29.3 to 9.0 events/h) at 12 months ^[172]^C4; THN3 showed sustained benefit at 3 years with median AHI reduction of 15.1-17.7 events/h and large effect sizes ^[182]^B2b.

is first-line for pediatric OSA. The CHAT trial demonstrated normalization of in 79% of children vs 46% with watchful waiting ^[119]^A1b; long-term risks of non-surgical management include growth failure (HR 1.97), developmental delay (HR 2.48), and ADHD (HR 1.66) ^[213]^B2b.

achieves substantial weight loss and OSA remission in obesity. At 5 years, one-anastomosis gastric bypass produced 86.6% OSA remission (mean BMI 30.1 kg/m²) ^[92]^B2a. Perioperative risk is increased in OSA patients (OR 4.3 for major adverse outcomes) ^[157]^B2b.

(daily 30 min for 3 months) reduced AHI from 22.4 to 13.7 events/h in moderate OSA ^[109]^A1b.

Positional therapy benefits supine-predominant OSA defined by AHI supine:non-supine ratio ≥4:1 and non-supine AHI <10 events/h ^[8]^C4.

Pharmacotherapy is emerging. FDA-approved wakefulness-promoting agent (37.5-300 mg/d) improves residual sleepiness in PAP-treated patients: MWT latency improved by 11.2 min, ESS by -4.6 points ^[197]^A1b. Novel combinations targeting OSA pathophysiology:

Drug	Dose	Key Trial	AHI Reduction
(arooxybutynin/atomoxetine)	2.5/75 mg or 5/75 mg nightly	SynAIRgy ^[170]^A1b	44.1% vs 17.6% placebo; median AHI from 19.6 to ~11 events/h
80 mg + 5 mg	Single night	Taranto-Montemurro ^[168]^A1b	63% (34-86%) reduction
	400 mg nightly	Hedner ^[110]^A1b	41% reduction; 40% achieved ≥50% reduction
	10-15 mg weekly	SURMOUNT-OSA ^[77]^A1b	-25.3 events/h (PAP-naive); -29.3 events/h (PAP users)
+	Not specified	RESCUE-Combo ^[121]^A1b	45% reduction in supine NREM AHI
	100 mg nightly	Smales ^[35]^A1b	AHI from 38.7 to 28.5 events/h

Weight loss is a critical adjunct. CPAP plus weight loss reduced systolic BP more than either alone ^[186]^A1b. GLP-1 agonist induced weight loss but did not reduce vascular inflammation; CPAP alone reduced aortic wall inflammation and unstable plaque volume ^[79]^A1b.

Step 4: Monitoring and Long-term Follow-up

Annual clinical review with objective adherence data for PAP. Repeat polysomnography if symptoms recur or weight changes >10%. Screen for cardiovascular complications, glaucoma (untreated OSA HR 1.27 for incident glaucoma) ^[161]^B2b, and thromboembolism in at-risk populations (PCOS: PE HR 1.95) ^[160]^B2b.

What NOT to Do

Do not use routine supplemental oxygen instead of CPAP; CPAP reduces blood pressure, oxygen does not ^[140]^A1b.
Do not rely on flexible pressure delivery (C-Flex, etc.) to improve adherence; meta-analysis shows no benefit ^[120]^A1a.
Do not initiate long-term NIV during acute hypercapnic respiratory failure; reassess at 2-4 weeks ^[3]^A1c.
Do not use to raise arousal threshold; trial showed no benefit ^[187]^A1b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
CPAP in asymptomatic patients	SAVE trial ^[118]^A1b: no reduction in cardiovascular events (HR 1.10)	RICCADSA ^[75]^A1b: on-treatment reduction in those with CPAP ≥4 h/night (HR 0.29); benefit modified by ΔHR ^[76]^B2b	Moderate	In asymptomatic patients with CAD and OSA, CPAP may benefit those with high pulse rate response to events; shared decision-making
Pharmacotherapy vs PAP	AD109 and other drugs show efficacy, but not yet first-line	CPAP remains gold standard; pharmacotherapy as adjunct or alternative	Mild	Pharmacotherapy is not currently recommended as first-line; may be used in CPAP-intolerant

Management Algorithm

Pearl: PAP therapy is the most effective treatment for OSA, but long-term success depends on adherence; integrate telemedicine, weight loss, and alternative therapies (oral appliances, hypoglossal nerve stimulation, or emerging pharmacotherapy) for patients who cannot tolerate or fail PAP.

Pharmacological Options for OSA

Drug	Dose	Key Trial	AHI Reduction
AD109 (arooxybutynin/atomoxetine)	2.5/75 mg or 5/75 mg nightly	SynAIRgy ^[170]^A1b	44.1% vs 17.6% placebo
Atomoxetine 80 mg + oxybutynin 5 mg	Single night	Taranto-Montemurro ^[168]^A1b	63% (34-86%) reduction
Sulthiame	400 mg nightly	Hedner ^[110]^A1b	41% reduction; 40% ≥50% reduction
Tirzepatide	10-15 mg weekly	SURMOUNT-OSA ^[77]^A1b	-25.3 events/h (PAP-naive); -29.3 events/h (PAP users)
Solriamfetol	37.5-300 mg daily	Schweitzer ^[184]^A1b; Strollo ^[197]^A1b	MWT improvement 11.2 min; ESS -4.6
Trazodone	100 mg nightly	Smales ^[35]^A1b	AHI from 38.7 to 28.5 events/h
Acetazolamide + eszopiclone	Not specified	RESCUE-Combo ^[121]^A1b	45% reduction in supine NREM AHI
Donepezil	Not specified	Moraes ^[117]^A1b	AHI improvement in Alzheimer patients

History and Evolution of Treatment

▸CPAP remains first-line, supported by trials showing cardiovascular benefit in adherent patients and those with high autonomic response; the SAVE trial did not show event reduction in unselected patients [118].
▸Pharmacotherapy has advanced from abandoned agents (protriptyline, theophylline) to promising noradrenergic/antimuscarinic combinations (AD109) and GLP-1 agonists (tirzepatide) that reduce AHI by 20-25 events/h [77, 170].
▸Hypoglossal nerve stimulation and adenotonsillectomy are effective for selected patients; atrial pacing and benzodiazepines have been abandoned after negative trials [119, 172, 219].

A half-century of randomized trials has transformed OSA treatment from empirical attempts to evidence-based therapies targeting specific pathophysiological traits. The current standard of care emerged through s that refined indications, while alternative approaches were abandoned or repurposed.

CPAP: The Gold Standard Established and Refined

(CPAP) was established as first-line therapy after trials consistently demonstrated improvements in sleepiness, quality of life, and blood pressure. The SAVE trial (n=2717) showed that CPAP plus usual care did not reduce cardiovascular events in patients with moderate-to-severe OSA and established cardiovascular disease (HR 1.10, 95% CI 0.91-1.32) ^[118]^A1b. However, the RICCADSA trial (n=244) in patients with coronary artery disease and nonsleepy OSA found that on-treatment analysis of CPAP use ≥4 h/night was associated with a 71% risk reduction (HR 0.29) ^[75]^A1b. A post-hoc analysis identified that patients with a higher pulse rate response to respiratory events (ΔHR >10 bpm) derived the greatest CPAP benefit ^[76]^B2b. The HeartBEAT trial (n=318) demonstrated a -2.4 mm Hg reduction in 24-hour mean arterial pressure with CPAP versus control ^[140]^A1b. The MORPHEOS trial (n=123) in patients with uncontrolled found CPAP improved office systolic BP by -10 ± 16 mm Hg and doubled the rate of 24-hour ABPM control (<130/80 mm Hg) from 20% to 40.7% (P=0.024) ^[200]^A1b. Telemedicine-based follow-up improves adherence: the Tele-OSA trial showed that proactive telemedicine increased PAP adherence to 4.3 h/night versus 4.1 h/night with standard care (P=0.01), with particular benefit in patients with depression ^[204]^A1b.

Pharmacotherapy: From Abandoned Agents to Noradrenergic Targets

Early pharmacological attempts largely failed. reduced daytime somnolence and improved nocturnal oxygenation but did not significantly decrease apnea frequency and caused anticholinergic side effects ^[218]^A1b. modestly reduced obstructive apneas but worsened sleep quality ^[216]^A1b. improved oxygenation during ethanol-exacerbated OSA but did not reduce apnea number ^[217]^A1b. 0.25 mg increased arousal threshold but prolonged apnea duration and lowered nadir oxygen saturation (80.1% vs 84.2%, P<0.001) ^[215]^A1b. These agents were abandoned due to limited efficacy or harm. The field shifted toward targeting neuromuscular control. The combination of and (ato-oxy) reduced AHI by 63% in a single-night proof-of-concept trial (n=20) ^[168]^A1b, and a 30-day study (n=39) confirmed tolerability with ~50% reduction in hypoxic burden ^[122]^A1b. The phase 2 MARIPOSA trial (n=211) of AD109 (aro-oxy) showed AHI reductions of -47.1% (2.5/75 mg) and -42.9% (5/75 mg) versus placebo (both P<0.0001) ^[181]^A1b. The phase 3 SynAIRgy trial (n=646) confirmed a mean treatment difference of -4.0 events/h (95% CI, -6.4 to -1.6) at 26 weeks ^[170]^A1b. , a carbonic anhydrase inhibitor, reduced AHI by -41.0% (400 mg) and -32.1% (200 mg) versus -5.4% placebo, but dose-dependent paresthesia led to 18% withdrawals ^[110]^A1b. The RESCUE-Combo trial (n=20) found that dual therapy with plus reduced supine NREM AHI by -45% (P=0.003), though adding did not further improve outcomes ^[121]^A1b. The GLP-1 receptor agonist (two phase 3 trials, n=469) produced -20.0 to -23.8 events/h reductions in AHI at 52 weeks, along with significant weight loss and improvements in hypoxic burden, hsCRP, and systolic BP, all P<0.001 ^[77]^A1b. In a proof-of-concept study (n=30), CPAP but not -mediated weight loss reduced vascular inflammation and unstable coronary plaque volume ^[79]^A1b. 100 mg reduced AHI from 38.7 to 28.5 events/h without worsening hypoxemia (P=0.041) ^[35]^A1b; showed no effect on arousal threshold or AHI overall ^[187]^A1b. 10 mg restored endothelial complement protection in OSA patients, suggesting a potential approach to reduce residual cardiovascular risk after CPAP ^[202]^A1b.

Surgical and Neuromodulatory Advances

was validated by the CHAT trial (n=464), which demonstrated improved symptoms, quality of life, and polysomnographic normalization (79% vs 46% with watchful waiting) but no improvement in executive function ^[119]^A1b. In children with mild SDB, watchful waiting showed only 13% PSG progression but 57% symptom persistence/progression over 1 year ^[127]^B2b. : the STAR trial (n=126) showed a 68% median reduction in AHI (29.3 to 9.0 events/h) at 12 months, with a randomized withdrawal confirming efficacy (AHI 25.8 vs 7.6 events/h, P<0.001) ^[172]^C4. The THN3 study (n=138) reported sustained improvements at 3 years (median AHI reduction -15.1/h at 24 months and -17.7/h at 36 months) ^[182]^B2b. The OSPREY randomized controlled trial (n=104) found that 58.2% of patients receiving proximal hypoglossal nerve stimulation achieved the primary endpoint (≥50% AHI reduction and AHI <20) versus 13.5% in controls (P<0.001) ^[229]^A1b. reduced AHI from 22.4 to 13.7 events/h (P<0.05) and improved snoring and sleepiness in moderate OSA (n=31) ^[109]^A1b. Combined and sleep hygiene (n=25) decreased AHI by 8.4 events/h in older adults with OSA, versus an increase of 8.1 events/h in controls (between-group difference 16.5 events/h, P=0.001) ^[228]^A1b.

Abandoned Approaches: Lessons from Negative Trials

initially appeared promising in a small unblinded study (n=15) showing reduced apnea-hypopnea index (P<0.001) ^[220]^B2b, but a well-designed randomized crossover trial (n=16) found no effect (change in AHI +0.2 events/h, P=0.87) and confirmed that CPAP was highly effective (-46.3 events/h, P<0.001) ^[219]^B2b. in children: a systematic review update found no controlled evidence supporting efficacy versus watchful waiting; the sole available RCT showed no significant AHI change ^[223]^A1a. These examples underscore the necessity of rigorous comparative effectiveness research before adopting new therapies.

Pearl: The history of OSA treatment teaches that only therapies addressing the underlying pathophysiological traits, whether mechanical (CPAP, surgery), neuromuscular (hypoglossal stimulation, noradrenergic drugs), or metabolic (weight loss), have proven durably effective; agents targeting arousal threshold or sedation alone consistently fail.

9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)

▸Transtracheal oxygen therapy (Lipkin method) matures in 7-10 days and reduces complications compared with the Seldinger technique.
▸High-intensity expiratory muscle strength training reduces AHI by 50.8% and improves systemic inflammation in moderate OSA.
▸High-flow nasal cannula during EBUS in high-risk OSA patients halves the rate of desaturation events without increasing hypercapnia.

HY High Yield: For every 1 cm H₂O increase in maximal expiratory pressure with EMST, AHI decreases by 0.149 points (p = 0.002), a 50 % reduction in AHI is achievable with high‑intensity training [235].

! Warning: Hypoglossal nerve stimulation lead migration into the pleural space occurs in <1 % of adverse events but can cause pneumothorax; preoperative imaging and multidisciplinary planning are mandatory [242].

Building on the evolution of surgical and device-based therapies, the pulmonologist’s distinctive toolkit for obstructive sleep apnea (OSA) extends beyond continuous positive airway pressure (CPAP) to include long-term oxygen support, pulmonary rehabilitation, and advanced interventional procedures. These modalities are especially relevant in overlap syndromes ( -OSA, ILD-OSA) and in patients with persistent hypoxemia or difficult airways.

Long-Term Oxygen Therapy and Home Ventilatory Support

Long-term oxygen therapy (LTOT) is indicated in OSA patients with chronic hypoxemia (PaO₂ ≤ 55 mm Hg or SpO₂ ≤ 88% at rest) or with evidence of pulmonary , particularly when coexisting COPD or is present . Transtracheal oxygen therapy (TTO) offers an alternative to nasal cannula in selected patients, providing more efficient and improved adherence. The Lipkin method for TTO, performed under conscious sedation, matures the tract in 7‑10 days (vs. 6‑8 weeks with the Seldinger technique), reducing minor complications . Home noninvasive ventilation (NIV) may be considered in OSA with chronic hypercapnic respiratory failure, though evidence for isolated OSA is limited; in overlap syndrome, NIV combined with CPAP can improve gas exchange .

Pulmonary Rehabilitation

Pulmonary rehabilitation (PR), a structured program of exercise training, education, and breathing exercises, is a powerful adjunct in OSA, particularly for patients with COPD-OSA overlap syndrome. A randomized controlled trial of 79 patients with overlap syndrome showed that adding 20 weeks of moderate‑intensity aerobic exercise to nightly PAP therapy significantly improved 6‑minute walk distance (6MWD), Barthel Index, body mass index, fat mass, and modified Medical Research Council dyspnea score (all p < 0.01). Additionally, the intervention group had a lower percentage of total sleep time with SpO₂ < 90% (p = 0.013) and higher lowest nocturnal SpO₂ (p = 0.008) .

A 6‑week PR program (including oropharyngeal exercises) combined with CPAP reduced neck, waist, and hip circumferences and improved pulmonary function compared with CPAP alone, despite no further change in apnea‑hypopnea index (AHI) . A home‑based graduated walking program over 6 months reduced AHI by a mean of 6 events/h, improved oxygen desaturation index (ODI), and lowered total cholesterol and LDL‑cholesterol .

Expiratory muscle strength training (EMST) is a novel, home‑based intervention. In a double‑blind trial of 31 men with moderate OSA, 12 weeks of high‑intensity EMST (50 % of maximal expiratory pressure, 25 breaths/day) reduced AHI by 50.8 % versus 6.3 % with low‑intensity EMST (p = 0.002, d = 1.31). For every 1 cm H₂O increase in maximal expiratory pressure, AHI decreased by 0.149 points (p = 0.002). High‑intensity EMST also reduced systemic oxidative stress (total oxidant status, oxidative stress index) and inflammation (TNF‑α, IL‑6) .

Interventional Pulmonology and Advanced Procedures

Flexible bronchoscopy plays a role in evaluating upper airway obstruction in selected OSA patients. In pediatric , bronchoscopy is frequently performed for OSA evaluation (38 % of cases) and reveals soft‑palate incompetence, tracheal bronchus, and laryngomalacia; complications are more common in children with cardiac anomalies or pulmonary hypertension (incidence rate ratio 3.76-4.2) . During endobronchial ultrasound (EBUS) in adults at high OSA risk (STOP‑Bang ≥ 3), the early procedural period (5-10 min) is critical for hypoxemia; high‑flow nasal cannula (HFNC) reduces desaturation events compared with conventional nasal cannula (50 % vs. 11.7 % with no desaturation, p = 0.007) without increasing hypercapnia .

Hypoglossal nerve stimulation (HGNS), a surgical therapy for PAP‑intolerant patients, carries device‑specific risks. A review of the FDA MAUDE database identified 151 respiratory‑sensing lead events among 765 HGNS adverse events; 75 involved lead migration, including 7 into the pleural space (< 1 % of all events) and 2 pneumothoraces. Preoperative imaging and multidisciplinary planning are essential .

Supraglottic jet oxygenation and ventilation (SJOV) via a Wei Nasal Jet Tube can maintain oxygenation during fiberoptic intubation in morbidly obese patients with OSA when mask ventilation fails, offering a rescue strategy for difficult airways .

Perioperative Risk Mitigation in OSA

Patients with OSA are at increased risk of perioperative pulmonary complications, especially when combined with interstitial lung disease (ILD) or pulmonary hypertension. Routine screening for OSA in ILD is recommended . Intraoperative lung‑protective ventilation, judicious fluid , and postoperative extubation to HFNC or NIV can reduce risk .

Pearl: In overlap syndrome (COPD-OSA), pulmonary rehabilitation (including aerobic exercise or expiratory muscle training) combined with PAP therapy improves functional capacity and sleep oxygenation more than PAP alone; all pulmonary rehabilitation programs should incorporate sleep assessment and targeted OSA interventions.

Pulmonary Rehabilitation Modalities in OSA: Evidence Summary

Modality	Population	Key Outcome	Reference
Moderate‑intensity aerobic exercise (20 wk)	COPD-OSA overlap	↑ 6MWD, ↑ Barthel Index, ↓ fat mass, ↓ TST <90%	^[234]^A1b
Oropharyngeal exercises + PR (6 wk)	Moderate‑severe OSA	↓ neck/waist/hip circumference, ↑ FEV1	^[236]^A1b
Home‑based graduated walking (6 mo)	Moderate‑severe OSA	↓ AHI by 6 events/h, ↓ LDL‑c, ↑ HDL‑c	^[237]^A1b
High‑intensity EMST (12 wk)	Moderate OSA (men)	↓ AHI 50.8%, ↓ TOS, ↓ TNF‑α, ↓ IL‑6	^[235]^A1b

10. Complications

▸OSA is a predictor of difficult intubation and life-threatening complications in the ICU, with a 11.3% incidence rate.
▸Obesity hypoventilation syndrome carries substantially higher mortality (OR 1.76) and length of stay (OR 3.05) among nonsurgical admissions.
▸Autonomic and cardiovascular complications (hypertension, arrhythmias, AAA expansion) are common and can be mitigated by CPAP therapy.

HY High Yield: The MACOCHA score (Mallampati, Apnea, Cervical spine, Coma, Hypoxia, Anesthesiologist) is a validated tool for predicting difficult intubation in the ICU.

Even after optimal respiratory support, patients with OSA remain at heightened risk for a spectrum of complications spanning cardiovascular, respiratory, and perioperative domains.

Respiratory Monitoring and Failure

The MACOCHA score identifies OSA as a predictor of difficult intubation, which occurs in 11.3% of ICU intubations and is associated with severe life-threatening complications (51% vs 36% in nondifficult intubations; P<0.0001) ^[246]^B2b. In patients with (OHS), excessive supplemental oxygen can precipitate acute hypercapnia, and excessive diuresis with loop diuretics exacerbates metabolic alkalosis, worsening hypoventilation ^[256]^D5. For overlap syndrome ( +OSA), initiation of home NIV reduced mortality by 33% compared to COPD alone ^[258]^B2b. Nocturnal hypoxemia is common; in pulmonary vascular disease, altitude exposure dropped mean SpO₂ from 91% to 83% and increased the oxygen desaturation index from 17 to 42 events/h ^[205]^A1b.

Autonomic and Cardiovascular Complications

Intermittent hypoxia drives endothelial dysfunction via miR-210 and SREBP2, contributing to and atherosclerosis ^[39]^C4^[91]^D5. In the Nationwide Inpatient Sample, sleep-disordered breathing was associated with increased LOS (OR 1.17, 95% CI 1.16-1.17) and costs (OR 1.67, 95% CI 1.66-1.67) but lower mortality (OR 0.79); OHS, however, had substantially increased mortality (OR 1.76) and LOS (OR 3.05) ^[255]^B2b. CPAP therapy reduces blood pressure (mean -2.4 mm Hg 24-hour MAP) ^[140]^A1b and improves pulmonary hypertension and left ventricular diastolic dysfunction in OHS ^[115]^A1b. Severe OSA (ODI >30) is independently associated with faster abdominal aortic aneurysm expansion (2.9 vs 1.2 mm/yr; P<0.05) ^[250]^B3b.

DVT/PE Prophylaxis and Pain

OSA patients are at increased risk for venous thromboembolism due to obesity and immobility; pharmacologic prophylaxis with low-molecular-weight or unfractionated heparin is standard. For pain, multimodal is preferred to minimize opioids. Dexmedetomidine is under investigation for preventing postoperative delirium in OSA patients ^[253]^D5. Neuromuscular blockade did not reduce opioid consumption in high-risk children undergoing adenotonsillectomy, and postoperative respiratory events occurred in 49% of the blockade group vs 59% of controls (aOR 0.55, 95% CI 0.26-1.12) ^[208]^A1b.

Hospital-Acquired Complications

Preoperative AHI and nocturnal hypoxemia parameters (ODI, CT90, minimum SpO₂) predict postoperative complications ^[174]^D5. Lung expansion maneuvers, early mobilization, and pressure injury prevention protocols are essential. In pregnant women with OSA, screening with BMI, age, and tongue enlargement is recommended to reduce maternal-fetal complications ^[129]^B2b.

Complication Table

Complication	Frequency	Prevention	Management
Difficult intubation in ICU	11.3% overall; OSA is predictor ^[246]^B2b	MACOCHA score, prepare difficult airway	Video laryngoscopy, fiberoptic intubation
Life-threatening complications with difficult intubation	51% vs 36% ^[246]^B2b	Avoid hypoxia, have rescue plan	Immediate desaturation protocol
Hypercapnia in OHS from excess O₂	Common error ^[256]^D5	Target SpO₂ 88-92%	Reduce FiO₂, initiate NIV
Increased LOS, costs, mortality in SDB/OHS admissions	LOS OR 1.17, costs OR 1.67, mortality OR 0.79 (SDB); mortality OR 1.76 (OHS) ^[255]^B2b	Optimize CPAP, monitor for complications	Early recognition, multidisciplinary care
Faster AAA expansion in severe OSA	2.9 vs 1.2 mm/yr (ODI>30) ^[250]^B3b	Screen for OSA in AAA patients	CPAP therapy, aneurysm surveillance

Pearl: In hospitalized OSA patients, the combination of obesity, opioids, and supine positioning can precipitate acute hypercapnic respiratory failure; avoid excessive supplemental oxygen and use NIV early when hypoventilation is suspected.

11. Prognosis and Natural History

▸Hypoxic burden and ventilatory burden independently predict cardiovascular events and mortality, with HRs of 1.45 and 1.13 per 1-SD increase.
▸CPAP adherence ≥4 h/night reduces cardiovascular risk by 71% in CAD patients with nonsleepy OSA (HR 0.29), but benefit is limited to those with high ΔHR.
▸Bariatric surgery resolves OSA in 86.6% of patients at 5 years, while pharmacotherapy with AD109 reduces AHI by 44.1%.

HY High Yield: Hypoxic burden (area under the desaturation curve) and ΔHR (pulse rate response to respiratory events) are stronger predictors of cardiovascular outcomes than AHI alone.

The complications detailed above underscore that OSA is not a benign condition; its natural history is marked by progressive cardiovascular, metabolic, and neurocognitive decline. Without treatment, the trajectory is driven by the cumulative burden of intermittent hypoxemia and ventilatory instability.

Untreated Trajectory

Hypoxic burden (HB) and ventilatory burden independently predict incident cardiovascular disease (CVD) and all-cause mortality. In the Multi-Ethnic Study of Atherosclerosis, each 1-SD increase in HB conferred a hazard ratio of 1.45 (95% CI 1.14-1.84) for CVD; in the MrOS cohort, the HR was 1.13 (1.02-1.26) ^[81]^B2b. The Pays de la Loire cohort reported that HB, but not symptom subtypes, predicted major adverse cardiovascular events (MACE) over a median 78 months (HR 1.21; 95% CI 1.07-1.38) ^[82]^B2b. Among patients with -OSA overlap syndrome (OVS), untreated OVS carried a HR of 1.74 (1.03-2.94) for all-cause mortality and a increase in exacerbation rate ^[101]^B2b. OSA is also associated with a 30% higher risk of lung cancer (HR 1.32) in studies with ≥5-year follow-up ^[80]^A1a. Cognitive decline is mediated by altered perivascular diffusivity: each 1-event/h increase in AHI corresponded to a 0.007 decrease in the DTI-ALPS index over 4 years, which in turn predicted worsening visual memory ^[78]^B2b. Comorbid insomnia and sleep apnea (COMISA) independently raises the odds of uncontrolled (OR 1.88) ^[105]^C4. Elevated circulating NLRP3 is associated with a HR of 1.46 (1.10-1.94) for incident chronic kidney disease ^[178]^B2b. Postoperatively, patients with >4.7% of sleep time with SpO₂ <90% have a 1.91-fold odds of cardiorespiratory complications or death ^[175]^B2b. Polysomnographic phenotypes refine risk beyond AHI: the “periodic limb movements” cluster (HR 2.02), “hypopnoea and hypoxia” (HR 1.74), and “combined severe” (HR 1.69) all independently predict CV outcomes ^[22]^B2b.

Treated Outcomes

Continuous positive airway pressure (CPAP) reduces 24-hour mean arterial pressure by -2.4 mm Hg (95% CI -4.7 to -0.1) in patients with CVD or multiple risk factors ^[140]^A1b. In the RICCADSA trial, CPAP in patients with CAD and nonsleepy OSA did not significantly reduce the primary endpoint (HR 0.80) in intention-to-treat analysis, but on-treatment analysis with ≥4 h/night use showed a HR of 0.29 (0.10-0.86); the benefit was concentrated in those with a pulse rate response to respiratory events (ΔHR) ≥1 SD above the mean ^[75]^A1b^[76]^B2b. CPAP also decreases aortic wall inflammation and low-attenuation coronary plaque volume ^[79]^A1b. In acutely decompensated heart failure, in-hospital CPAP improved LVEF by 4.5% (SE 1.7%) ^[183]^A1b. Upper-airway stimulation reduces AHI by 68% (from 29.3 to 9.0 events/h) and improves quality of life ^[172]^C4. The combination aroxybutynin-atomoxetine (AD109) produced a 44.1% decrease in AHI at 26 weeks (median treatment difference -4.0 events/h; 95% CI -6.4 to -1.6) ^[170]^A1b. A meta-analysis of atomoxetine combination therapy showed a mean AHI reduction of -5.83 events/h (95% CI -9.05 to -2.62) ^[192]^A1a. In children, adenotonsillectomy normalizes in 79% versus 46% with watchful waiting ^[119]^A1b. Bariatric surgery resolves OSA in 86.6% of patients at 5 years ^[92]^B2a.

Factors That Bend the Curve

Adherence to CPAP is the single strongest modifiable factor: peer-driven interventions improved mean nightly use from 3.7 to 4.5 h (P=0.014) ^[195]^A1b. The hypoxic burden and ΔHR identify patients most likely to derive cardiovascular benefit from CPAP ^[76]^B2b^[81]^B2b. Obesity, comorbid cardiometabolic disease, and smoking history blunt the response and increase mortality ^[102]^B2b^[101]^B2b. Primary care-based achieves similar outcomes to specialist care at lower cost ^[142]^A1a.

Pearl: The hypoxic burden captured by nocturnal oximetry (e.g., T90 >4.7%) and the pulse rate response to respiratory events (ΔHR) identify patients with OSA at highest cardiovascular risk and those most likely to benefit from CPAP; these metrics should guide treatment intensity and monitoring.

12. Special Populations and Pregnancy

▸Pediatric OSA: PSG remains gold standard, but HSAT is recommended for children >5 years when PSG unavailable; montelukast 4-5 mg daily for 16 weeks reduces AHI by ~50% in mild-to-moderate disease.
▸Pregnancy: OSA prevalence triples by third trimester; screening using BMI, age, and tongue enlargement is effective; PAP is safe but adherence is often <4 h/night.
▸Peri-operative: Stop-Bang ≥3 has 93% sensitivity for moderate-to-severe OSA; OSA increases postoperative hypoxemia (OR 7.9) and ICU transfer risk; continue PAP perioperatively.

The long-term cardiovascular and neurocognitive consequences of untreated OSA underscore the importance of tailored in vulnerable populations, where diagnostic thresholds, treatment safety, and expected outcomes differ substantially.

Pediatrics

(PSG) remains the recommended diagnostic standard for pediatric OSA ^[7]^A1c. When PSG is unavailable, home sleep apnea testing (HSAT) is recommended for otherwise healthy children over 5 years of age ^[7]^A1c; nocturnal oximetry with neural-network analysis can also accurately identify severity ^[267]^B2b. Adenotonsillectomy (AT) is first-line therapy, but up to 40% of children have persistent OSA postoperatively ^[2]^A1c. Residual disease is independently predicted by obesity (BMI ≥ 95th percentile; OR 3.12), severe baseline AHI, and concurrent asthma ^[282]^B3b. For children with mild-to-moderate OSA, montelukast (4 or 5 mg daily for 16 weeks) reduced AHI from 9.2 ± 4.1 to 4.2 ± 2.8 events/h (P < 0.0001) ^[264]^A1b; intranasal corticosteroids (fluticasone, budesonide) also show short-term benefit ^[96]^A1a. Untreated OSA is associated with growth failure (HR 1.97), delayed developmental milestones (HR 2.48), and ADHD (HR 1.66) over 10 years; AT attenuates these risks ^[213]^B2b. Endotype analysis reveals that Black children exhibit greater pharyngeal collapsibility and Asian children reduced dilator compensation, partially explaining racial disparities in REM AHI ^[201]^B2b. Neighborhood poverty and single‑female-headed households are strong confounders of the race-AHI association ^[278]^B3b. (OR 2.24) ^[281]^A1a and syndromic craniofacial conditions (e.g., cleft palate, ) require specialized multidisciplinary evaluation ^[93]^B2a^[259]^D5.

Pregnancy

OSA prevalence rises from 10.7% in the first trimester to 24.1% in the third trimester ^[129]^B2b. A validated screening model combining BMI, age, and tongue enlargement yields AUC 0.86-0.87 ^[129]^B2b. OSA is associated with a 4.7-fold increased odds of gestational diabetes (OR 4.71); the risk is particularly linked to REM‑related events (OR 2.09 per unit REM AHI) ^[279]^B3b. Positive airway pressure (PAP) therapy is safe during pregnancy, but adherence is suboptimal: in a pilot trial of , mean use was 3.1 ± 2.5 h/night, with only 38.4% of nights ≥ 4 h ^[265]^A1b. No significant differences in 24-hour blood pressure or adverse maternal/fetal outcomes were observed between PAP and nasal dilator strip groups ^[265]^A1b. Weight loss and oral appliances are reserved for the postpartum period; no specific teratogenicity concerns apply to PAP.

Elderly

In cognitively normal older adults (age 55-90 years), OSA severity indices (AHIall, AHI4%) are associated with accelerated amyloid β accumulation over 2 years (P < 0.05), suggesting a modifiable risk pathway for Alzheimer disease ^[144]^B2b. Lower 25‑hydroxyvitamin D levels are not independently associated with OSA after adjusting for BMI and neck circumference ^[280]^C4. Treatment should follow standard adult guidelines, but attention to polypharmacy, fall risk, and tolerance of PAP is critical. Mild OSA may warrant therapy to mitigate cognitive decline, though randomized evidence is lacking.

Immunocompromised

No specific contraindications to standard OSA therapy exist in immunocompromised patients. However, meticulous cleaning of PAP equipment is essential to reduce infection risk. Anti-inflammatory agents (montelukast, intranasal corticosteroids) may be used cautiously, but data in this population are absent.

Peri-operative

OSA is independently associated with postoperative hypoxemia (OR 7.9), ICU transfer (OR 4.43), and longer hospital stay (OR 1.65) ^[227]^B2b. Preoperative polysomnography parameters, AHI, oxygen desaturation index, CT90, minimum SpO₂, predict complications ^[174]^D5. STOP-Bang screening is recommended for all surgical patients; a score ≥ 3 identifies moderate-to-severe OSA with 93% sensitivity ^[14]^D5. Perioperative management includes continuation of PAP, preference for regional anesthesia, avoidance of supine positioning, and minimal opioid use ^[88]^D5^[154]^D5. In bariatric surgery cohorts, a diagnosis of OSA independently increases the risk of major adverse outcomes ^[157]^B2b.

Pearl: In children, residual OSA after adenotonsillectomy is common (≈27%) and predicted by obesity, severe baseline AHI, and asthma, mandating postoperative polysomnography in these subgroups ^[263]^B2b^[282]^B3b.

13. Prevention, Screening & Surveillance

▸Routine screening for OSA in the general population is not recommended (Grade 1A); target high-risk groups: acromegaly, perioperative, COPD, type 2 diabetes with obesity, and postoperative atrial fibrillation.
▸In hospitalized heart failure patients, STOP-BAG, Berlin Questionnaire, and Epworth Sleepiness Scale perform poorly; objective sleep testing is preferred.
▸Post-treatment surveillance PSG is critical in children after adenotonsillectomy because 26.8% have residual OSA, especially if obese, severe baseline AHI, or comorbid asthma.

HY High Yield: In acromegaly, STOP-Bang ≥3 has 93.3% sensitivity and 87.5% negative predictive value for moderate-to-severe OSA; post-surgical improvement in OSA correlates with IGF-1 decline [288].

! Warning: Do not use STOP-BAG, Berlin Questionnaire, or ESS alone to screen for OSA in hospitalized patients with heart failure, they add no predictive value beyond demographic/cardiovascular variables [292].

From special populations, the focus shifts to systematic strategies for reducing the burden of OSA. Prevention is primarily secondary, identifying undiagnosed disease in high-risk groups, rather than primary, because the principal modifiable risk factor (obesity) is a complex societal challenge. For the diagnosed patient, surveillance ensures treatment efficacy and detects complications.

Primary Prevention

No high-quality trial has demonstrated that any intervention prevents the development of OSA in asymptomatic individuals. Weight loss reduces AHI severity in those with established disease, but preventing weight gain in the general population has not been studied as a preventive strategy for OSA. The 2026 Chinese Thoracic Society guideline recommends against routine screening for OSA in the general population without high-risk features (Grade 1, A) ^[291]^A1c. Smoking cessation may improve sleep architecture, N1 stage is reduced in abstainers at 6 months, and long-term nicotine patches are associated with increased slow-wave sleep ^[285]^D5, but evidence for OSA prevention is indirect.

Screening for Undiagnosed OSA

Screening is recommended for individuals with typical OSA symptoms (habitual snoring, witnessed apneas, daytime sleepiness), physical signs (obesity, increased neck circumference, retrognathia), or high-risk comorbidities ^[291]^A1c. Specific high-risk groups include:

Patients with : STOP-Bang score ≥3 has sensitivity 93.3% and negative predictive value 87.5% for detecting moderate-to-severe OSA (REI ≥15/h) ^[288]^B2b.
Perioperative patients (especially bariatric surgery candidates): screening is recommended Grade 1, A ^[291]^A1c.
Type 2 diabetes with obesity and type 1 diabetes: Screening for OSA by questioning is recommended preconception (Grade C expert consensus) ^[287]^A1c.
Postoperative : OSA is an independent predictor of AF recurrence after non-cardiac surgery (HR not reported, but association significant) ^[98]^B3b.
Atrial fibrillation undergoing ablation: Nurse-led integrated care increased OSA diagnosis compared to usual care ^[283]^A1b.

Screening tools perform variably in different populations. In hospitalized patients with heart failure, the STOP-BAG, Berlin Questionnaire, and Epworth Sleepiness Scale added no predictive value beyond demographic and cardiovascular parameters (AUC 0.688, 95%) ^[292]^C4. Therefore, in HF patients, objective sleep testing rather than questionnaire-based screening is recommended.

Surveillance of Diagnosed Patients

After initiating treatment, follow-up (PSG) is indicated to confirm therapeutic efficacy. In children undergoing adenotonsillectomy, residual OSA (postoperative AHI ≥2/h) occurs in 26.8% of cases; independent risk factors are obesity (OR 3.12), severe baseline AHI (OR 1.08 per unit AHI), and concurrent asthma (OR 1.95, 95% CI 1.12-3.40) ^[282]^B3b. Postoperative PSG at 6-12 months is recommended for these high-risk groups.

In adults with severe OSA (ODI >30), faster abdominal aortic aneurysm expansion was observed (median 2.9 mm/yr vs 1.2 mm/yr in mild/no OSA), suggesting that surveillance for cardiovascular complications may be warranted, though no randomized trial has proven that OSA treatment reduces expansion ^[250]^B3b.

Patient Education

Key counseling points include: (1) Weight loss of 5-10% significantly reduces AHI; (2) Smoking cessation improves sleep quality and may reduce OSA severity; (3) CPAP adherence is essential for cardiovascular risk reduction; (4) In patients with acromegaly, surgical remission improves OSA severity (median REI reduction -9.5/h, 95% CI -13.3 to -5.3) ^[288]^B2b; (5) Vaccination reduces hospitalization risk more in OSA patients than controls (absolute risk reduction 13.3% vs 6.3%) ^[289]^B2c.

Pearl: For patients with heart failure, do not rely on symptom-based screening questionnaires, proceed directly to objective sleep testing; in , sleep testing is associated with a mortality benefit (NNT ≈ 33 over 5 years), but anticipate increased nonfatal events from higher healthcare engagement.

High-Risk Populations for OSA Screening

Population	Rationale	Screening Tool	Grade
General population (no risk factors)	Low prevalence, no benefit	None	1 A against screening ^[291]^A1c
Typical OSA symptoms/signs	High pretest probability	Clinical evaluation + PSG	1 A ^[291]^A1c
Acromegaly	68.6% have OSA, STOP-Bang sensitive	STOP-Bang ≥3	2 B ^[288]^B2b
Perioperative (bariatric, high-risk)	Risk of perioperative complications	Polysomnography	1 A ^[291]^A1c
COPD with high likelihood of OSA	Sleep testing associated with lower mortality	PSG	2 B ^[290]^B3b
Heart failure (hospitalized)	40-50% prevalence; questionnaires fail	Cardiorespiratory test	2 B ^[292]^C4
Type 2 diabetes + obesity	Preconception screening recommended	Questioning	C Expert ^[287]^A1c
Postoperative atrial fibrillation	OSA predicts AF recurrence	PSG if symptomatic	2 C ^[98]^B3b

References

[1]
Mokhlesi B, Masa JF, Brozek JL et al.. “Evaluation and Management of Obesity Hypoventilation Syndrome. An Official American Thoracic Society Clinical Practice Guideline.” American journal of respiratory and critical care medicine (2019). PMID: 31368798 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment, 10. Complications
[2]
Ehsan Z, Ishman SL, Soghier I et al.. “Management of Persistent, Post-adenotonsillectomy Obstructive Sleep Apnea in Children: An Official American Thoracic Society Clinical Practice Guideline.” American journal of respiratory and critical care medicine (2024). PMID: 37890009 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment, 12. Special Populations & Pregnancy
[3]
Macrea M, Oczkowski S, Rochwerg B et al.. “Long-Term Noninvasive Ventilation in Chronic Stable Hypercapnic Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline.” American journal of respiratory and critical care medicine (2020). PMID: 32795139 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications, 11. Prognosis and Natural History
[4]
Hudgel DW, Patel SR, Ahasic AM et al.. “The Role of Weight Management in the Treatment of Adult Obstructive Sleep Apnea. An Official American Thoracic Society Clinical Practice Guideline.” American journal of respiratory and critical care medicine (2018). PMID: 30215551 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature
[5]
Mukherjee S, Patel SR, Kales SN et al.. “An Official American Thoracic Society Statement: The Importance of Healthy Sleep. Recommendations and Future Priorities.” American journal of respiratory and critical care medicine (2015). PMID: 26075423 ↗
L5GUIDELINECited in: 1. Definition, Classification and Nomenclature
[6]
Ng SSS, Tam WWS, Lee RWW et al.. “Effect of Weight Loss and Continuous Positive Airway Pressure on Obstructive Sleep Apnea and Metabolic Profile Stratified by Craniofacial Phenotype: A Randomized Clinical Trial.” American journal of respiratory and critical care medicine (2022). PMID: 34936531 ↗
L1RCTCited in: 1. Definition, Classification and Nomenclature
[7]
MacLean JE, Adeleye A, Van Dam A et al.. “The Canadian Thoracic Society/Canadian Sleep Society Guideline on the diagnosis of obstructive sleep apnea in children.” Chest (2026). PMID: 41887281 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 12. Special Populations & Pregnancy
[8]
Joosten SA, O'Donoghue FJ, Rochford PD et al.. “Night-to-night repeatability of supine-related obstructive sleep apnea.” Annals of the American Thoracic Society (2014). PMID: 24720558 ↗
L4RCTCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[9]
Bamagoos AA, Cistulli PA, Sutherland K et al.. “Polysomnographic Endotyping to Select Patients with Obstructive Sleep Apnea for Oral Appliances.” Annals of the American Thoracic Society (2019). PMID: 31394914 ↗
L4RCTCited in: 1. Definition, Classification and Nomenclature
[10]
Schmickl CN, Orr JE, Sands SA et al.. “Loop Gain as a Predictor of Blood Pressure Response in Patients Treated for Obstructive Sleep Apnea: Secondary Analysis of a Clinical Trial.” Annals of the American Thoracic Society (2024). PMID: 37938917 ↗
L2TRIAL_NONRANDOMCited in: 1. Definition, Classification and Nomenclature
[11]
Xu H, Liu F, Li Z et al.. “Genome-Wide Association Study of Obstructive Sleep Apnea and Objective Sleep-related Traits Identifies Novel Risk Loci in Han Chinese Individuals.” American journal of respiratory and critical care medicine (2022). PMID: 35819321 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature
[12]
Lechat B, Naik G, Reynolds A et al.. “Multinight Prevalence, Variability, and Diagnostic Misclassification of Obstructive Sleep Apnea.” American journal of respiratory and critical care medicine (2022). PMID: 34904935 ↗
L4OTHERCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[13]
Kendzerska T, Radhakrishnan D, Amin R et al.. “Obstructive Sleep Apnea and Mental Health Disorders in the Pediatric Population: A Retrospective, Population-based Cohort Study.” Annals of the American Thoracic Society (2024). PMID: 38669619 ↗
L2COHORTCited in: 1. Definition, Classification and Nomenclature, 12. Special Populations & Pregnancy
[14]
Chung F, Abdullah HR, Liao P. “STOP-Bang Questionnaire: A Practical Approach to Screen for Obstructive Sleep Apnea.” Chest (2016). PMID: 26378880 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 12. Special Populations & Pregnancy
[15]
Wickwire EM, Collop NA. “Insomnia and sleep-related breathing disorders.” Chest (2010). PMID: 20525657 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors
[16]
Dyken ME, Afifi AK, Lin-Dyken DC. “Sleep-related problems in neurologic diseases.” Chest (2012). PMID: 22315121 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 6. Severity, Staging and Risk Stratification
[17]
Teodorescu M, Polomis DA, Hall SV et al.. “Association of obstructive sleep apnea risk with asthma control in adults.” Chest (2010). PMID: 20495105 ↗
L4OTHERCited in: 1. Definition, Classification and Nomenclature
[18]
Ibrahim LH, Patel SR, Modarres M et al.. “A measure of ventilatory variability at wake-sleep transition predicts sleep apnea severity.” Chest (2008). PMID: 18347208 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature
[19]
Mysliwiec V, Gill J, Lee H et al.. “Sleep disorders in US military personnel: a high rate of comorbid insomnia and obstructive sleep apnea.” Chest (2013). PMID: 23681455 ↗
L4OTHERCited in: 1. Definition, Classification and Nomenclature
[20]
Brunetti L, Tesse R, Miniello VL et al.. “Sleep-disordered breathing in obese children: the southern Italy experience.” Chest (2010). PMID: 20139225 ↗
L4OTHERCited in: 1. Definition, Classification and Nomenclature
[21]
Pihtili A, Glantz H, Thunström E et al.. “CPAP therapy may improve HFpEF-like features in coronary artery disease with obstructive sleep apnea: A randomized controlled trial.” Sleep medicine (2026). PMID: 42250441 ↗
L1RCTCited in: 1. Definition, Classification and Nomenclature
[22]
Zinchuk AV, Jeon S, Koo BB et al.. “Polysomnographic phenotypes and their cardiovascular implications in obstructive sleep apnoea.” Thorax (2017). PMID: 28935698 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[23]
Abdelaal A, Mahmoud YA, Alsouri W et al.. “Bidirectional association between obstructive sleep apnea and diabetic retinopathy: a severity-stratified systematic review and meta-analysis with GRADE assessment.” Acta diabetologica (2026). PMID: 42334598 ↗
L3SR_OBSCited in: 1. Definition, Classification and Nomenclature, 11. Prognosis and Natural History
[24]
Sung C, Kim HC, Lee HB et al.. “Drug-induced sleep endoscopy in obstructive sleep apnea: a systematic review and meta-analysis of sedative agents, monitoring methods, and administration techniques.” Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine (2026). PMID: 42298088 ↗
L4SR_OBSCited in: 1. Definition, Classification and Nomenclature
[25]
Mustafa M. “Sleep-related problems among patients with rheumatoid arthritis in the World Health Organization Eastern Mediterranean region: a systematic review and meta-analysis.” Frontiers in psychiatry (2026). PMID: 42290998 ↗
L4SR_OBSCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation
[26]
Zhu Y, Luo Y, Du R et al.. “The association between obstructive sleep apnea syndrome and sarcopenia: a meta-analysis.” Frontiers in medicine (2026). PMID: 42180727 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature
[27]
Jin Y, Xu J, Yue H et al.. “Performance evaluation of finger-worn devices for sleep stage classification and sleep apnea detection: a systematic review and meta-analysis.” Journal of translational medicine (2026). PMID: 42141446 ↗
L5SR_OBSCited in: 1. Definition, Classification and Nomenclature
[28]
Malhotra A, Sterling KL, Cistulli PA et al.. “Dose-Response Relationship between Obstructive Sleep Apnea Therapy Adherence and Healthcare Utilization.” Annals of the American Thoracic Society (2023). PMID: 36735928 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue
[29]
Athar W, Card ME, Charokopos A et al.. “Obstructive Sleep Apnea and Pain Intensity in Young Adults.” Annals of the American Thoracic Society (2020). PMID: 32644865 ↗
L4OTHERCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification
[30]
Cohen O, Kundel V, Barbé F et al.. “The Great Controversy of Obstructive Sleep Apnea Treatment for Cardiovascular Risk Benefit: Advancing the Science through Expert Consensus: An Official American Thoracic Society Workshop Report.” Annals of the American Thoracic Society (2025). PMID: 39513996 ↗
L1OTHERCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[31]
Pendharkar SR, Sharpe H, Rosychuk RJ et al.. “Temporal and Regional Trends in Obstructive Sleep Apnea Using Administrative Health Data in Alberta, Canada.” Annals of the American Thoracic Society (2023). PMID: 36516070 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature
[32]
Mavroudis I, Petridis F, Ciobica A et al.. “Sexsomnia: an umbrella review of clinical, neurophysiological and diagnostic evidence.” Frontiers in neurology (2026). PMID: 42246051 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[33]
Mohsen Y, Novikov I, Sabareesan S et al.. “Documented Obstructive Sleep Apnea, Cardiometabolic Phenotype, and Rhythm-Related Outcomes After Atrial Fibrillation Ablation: An Observational Cohort Study.” Journal of arrhythmia (2026). PMID: 42382280 ↗
L2COHORTCited in: 1. Definition, Classification and Nomenclature
[34]
Stöwhas AC, Namdar M, Biaggi P et al.. “The effect of simulated obstructive apnea and hypopnea on aortic diameter and BP.” Chest (2011). PMID: 21393398 ↗
L4RCTCited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management
[35]
Smales ET, Edwards BA, Deyoung PN et al.. “Trazodone Effects on Obstructive Sleep Apnea and Non-REM Arousal Threshold.” Annals of the American Thoracic Society (2015). PMID: 25719754 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[36]
Op de Beeck S, Dieltjens M, Azarbarzin A et al.. “Mandibular Advancement Device Treatment Efficacy Is Associated with Polysomnographic Endotypes.” Annals of the American Thoracic Society (2021). PMID: 32946702 ↗
L2TRIAL_NONRANDOMCited in: 2. Pathophysiology and Mechanism
[37]
Soghier I, Brożek JL, Afshar M et al.. “Noninvasive Ventilation versus CPAP as Initial Treatment of Obesity Hypoventilation Syndrome.” Annals of the American Thoracic Society (2019). PMID: 31365842 ↗
L1SR_OBSCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[38]
Kakazu MT, Soghier I, Afshar M et al.. “Weight Loss Interventions as Treatment of Obesity Hypoventilation Syndrome. A Systematic Review.” Annals of the American Thoracic Society (2020). PMID: 31978317 ↗
L1SR_OBSCited in: 2. Pathophysiology and Mechanism
[39]
Shang F, Wang SC, Gongol B et al.. “Obstructive Sleep Apnea-induced Endothelial Dysfunction Is Mediated by miR-210.” American journal of respiratory and critical care medicine (2023). PMID: 36191258 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism, 10. Complications
[40]
Tolbert TM, Schmickl CN, Gell LK et al.. “Research Priorities for Translating Endophenotyping of Adult Obstructive Sleep Apnea to the Clinic: An Official American Thoracic Society Research Statement.” American journal of respiratory and critical care medicine (2025). PMID: 40737283 ↗
L1OTHERCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors
[41]
Katz ES, Mitchell RB, D'Ambrosio CM. “Obstructive sleep apnea in infants.” American journal of respiratory and critical care medicine (2011). PMID: 22135346 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[42]
Op de Beeck S, Wellman A, Dieltjens M et al.. “Endotypic Mechanisms of Successful Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea.” American journal of respiratory and critical care medicine (2021). PMID: 32970962 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism
[43]
Prasad B, Nyenhuis SM, Imayama I et al.. “Asthma and Obstructive Sleep Apnea Overlap: What Has the Evidence Taught Us?” American journal of respiratory and critical care medicine (2020). PMID: 31841642 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors
[44]
Edwards BA, Redline S, Sands SA et al.. “More Than the Sum of the Respiratory Events: Personalized Medicine Approaches for Obstructive Sleep Apnea.” American journal of respiratory and critical care medicine (2019). PMID: 31022356 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation
[45]
Díaz-García E, García-Tovar S, Alfaro E et al.. “Inflammasome Activation: A Keystone of Proinflammatory Response in Obstructive Sleep Apnea.” American journal of respiratory and critical care medicine (2022). PMID: 35363597 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism
[46]
Malhotra A, Schwartz AR, Schneider H et al.. “Research Priorities in Pathophysiology for Sleep-disordered Breathing in Patients with Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Research Statement.” American journal of respiratory and critical care medicine (2018). PMID: 29388824 ↗
L1REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[47]
Sands SA, Edwards BA, Terrill PI et al.. “Phenotyping Pharyngeal Pathophysiology using Polysomnography in Patients with Obstructive Sleep Apnea.” American journal of respiratory and critical care medicine (2018). PMID: 29327943 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism
[48]
Altaf QA, Dodson P, Ali A et al.. “Obstructive Sleep Apnea and Retinopathy in Patients with Type 2 Diabetes. A Longitudinal Study.” American journal of respiratory and critical care medicine (2017). PMID: 28594570 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism
[49]
Reutrakul S, Mokhlesi B. “Obstructive Sleep Apnea and Diabetes: A State of the Art Review.” Chest (2017). PMID: 28527878 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 10. Complications
[50]
Patil SP, Schneider H, Schwartz AR et al.. “Adult obstructive sleep apnea: pathophysiology and diagnosis.” Chest (2007). PMID: 17625094 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment, 10. Complications
[51]
Parish JM. “Genetic and immunologic aspects of sleep and sleep disorders.” Chest (2013). PMID: 23648914 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[52]
Chan AS, Lee RW, Cistulli PA. “Dental appliance treatment for obstructive sleep apnea.” Chest (2007). PMID: 17699143 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[53]
Kawata N, Tatsumi K, Terada J et al.. “Daytime hypercapnia in obstructive sleep apnea syndrome.” Chest (2007). PMID: 18079218 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification
[54]
Kuźniar TJ, Morgenthaler TI. “Treatment of complex sleep apnea syndrome.” Chest (2012). PMID: 23032455 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[55]
Beatty CJ, Wong AM, Landry SA et al.. “The Impact of Weight Loss on the Physiological Endotypes Associated With OSA.” Chest (2026). PMID: 41713777 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism
[56]
Hoffman M, Schulman DA. “The appearance of central sleep apnea after treatment of obstructive sleep apnea.” Chest (2012). PMID: 22871763 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[57]
Luo YM, Tang J, Jolley C et al.. “Distinguishing obstructive from central sleep apnea events: diaphragm electromyogram and esophageal pressure compared.” Chest (2008). PMID: 19118271 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism
[58]
Van de Steen L, Van den Ende M, Bou Kheir G et al.. “Circadian rhythm disturbances in nocturia and nocturnal polyuria: A systematic review.” Autonomic neuroscience : basic & clinical (2026). PMID: 42090872 ↗
L2SR_OBSCited in: 2. Pathophysiology and Mechanism
[59]
Fei H, Cheng G, Zeng Y et al.. “Chronic Cerebral Hypoxia and Cognitive Impairment: A Systematic Review and Meta-Analysis Based on Chronic Mountain Sickness, Anemia, Chronic Obstructive Pulmonary Disease, and Obstructive Sleep Apnea.” CNS neuroscience & therapeutics (2026). PMID: 41992647 ↗
L2SR_OBSCited in: 2. Pathophysiology and Mechanism
[60]
Lin CH, Hang LW, Finnsson E et al.. “Pathological Endotypic Traits of Paediatric Obstructive Sleep Apnea: Age and Sex Differences.” Respirology (Carlton, Vic.) (2025). PMID: 40937486 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism
[61]
Lal C, Weaver TE, Bae CJ et al.. “Excessive Daytime Sleepiness in Obstructive Sleep Apnea. Mechanisms and Clinical Management.” Annals of the American Thoracic Society (2021). PMID: 33621163 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 6. Severity, Staging and Risk Stratification
[62]
Imayama I, Prasad B. “Role of Leptin in Obstructive Sleep Apnea.” Annals of the American Thoracic Society (2017). PMID: 28796527 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors
[63]
Deacon NL, Jen R, Li Y et al.. “Treatment of Obstructive Sleep Apnea. Prospects for Personalized Combined Modality Therapy.” Annals of the American Thoracic Society (2016). PMID: 26569377 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management
[64]
İnam MG, İnam O, Lin JM et al.. “Predicting the presence and severity of obstructive sleep apnea with optical coherence tomography.” Annals of the American Thoracic Society (2026). PMID: 41025935 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[65]
Jaoude P, Vermont LN, Porhomayon J et al.. “Sleep-disordered breathing in patients with post-traumatic stress disorder.” Annals of the American Thoracic Society (2015). PMID: 25535907 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation
[66]
Giatti S, Santos RB, Aielo AN et al.. “Association of Sodium with Obstructive Sleep Apnea. The ELSA-Brasil Study.” Annals of the American Thoracic Society (2021). PMID: 33090879 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism
[67]
Zhang P, Liang D. “Effects of modified uvulopalatopharyngoplasty combined with pharyngeal and genioglossus exercises on sleep quality, cognitive function, and quality of life in patients with obstructive sleep apnea-hypopnea syndrome: a retrospective study.” Frontiers in surgery (2026). PMID: 42305806 ↗
L2COHORTCited in: 2. Pathophysiology and Mechanism
[68]
Wang J, Cheng Z, Du J et al.. “Biventricular dysfunction and blood oxygenation deficits in obstructive sleep apnea: a prospective study with non-contrast cardiac MRI.” BMC medical imaging (2026). PMID: 42226066 ↗
L2COHORTCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue
[69]
Yi H, Drager LF, Wang X et al.. “SLEEP-DISORDERED BREATHING IN HEART FAILURE: PHENOTYPES, MECHANISMS, AND PRECISION APPROACH.” Journal of cardiac failure (2026). PMID: 42431393 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[70]
Zhang CT, Ye YX, Huang XX et al.. “Intermittent hypoxia drives lung microbiome-metabolome remodeling to create a pro-inflammatory landscape in murine OSAHS.” Frontiers in microbiology (2026). PMID: 42422729 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism
[71]
Peng C, Sun X, Zhang Z et al.. “Chronic intermittent hypoxia impairs glymphatic function in male mice through ENT-dependent adenosine dysregulation.” Sleep (2026). PMID: 42412752 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism
[72]
Zhu W, Hou Y, Yang C et al.. “METTL3 suppresses pyroptosis in obstructive sleep apnea-associated hypertension via YTHDF2-mediated SOX4 mRNA degradation.” Journal of physiology and biochemistry (2026). PMID: 42384250 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism
[73]
Vakka A, Kyriakoulis KG, Tatakis F et al.. “Pleiotropic effects of renal denervation beyond blood pressure reduction.” Hypertension research : official journal of the Japanese Society of Hypertension (2026). PMID: 42362815 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism
[74]
Boltaboyeva A, Amangeldy B, Baigarayeva Z et al.. “Frailty-Driven Prediction of Inpatient Obstructive Sleep Apnea and Related Sleep Disorder Diagnoses Using Explainable AI.” Biomedicines (2026). PMID: 42351732 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism
[75]
Peker Y, Glantz H, Eulenburg C et al.. “Effect of Positive Airway Pressure on Cardiovascular Outcomes in Coronary Artery Disease Patients with Nonsleepy Obstructive Sleep Apnea. The RICCADSA Randomized Controlled Trial.” American journal of respiratory and critical care medicine (2016). PMID: 26914592 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[76]
Azarbarzin A, Zinchuk A, Wellman A et al.. “Cardiovascular Benefit of Continuous Positive Airway Pressure in Adults with Coronary Artery Disease and Obstructive Sleep Apnea without Excessive Sleepiness.” American journal of respiratory and critical care medicine (2022). PMID: 35579605 ↗
L2RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[77]
Malhotra A, Grunstein RR, Fietze I et al.. “Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.” The New England journal of medicine (2024). PMID: 38912654 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications
[78]
Lee MH, Lee WJ, Lee SK et al.. “Impact of Sleep Apnea on Perivascular Diffusivity and Cognition: A 4-Year Prospective Cohort Study.” American journal of respiratory and critical care medicine (2025). PMID: 40788707 ↗
L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[79]
O'Donnell C, Crilly S, O'Mahony A et al.. “Continuous Positive Airway Pressure but Not GLP1-mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea: A Randomized Proof-of-Concept Study.” Annals of the American Thoracic Society (2024). PMID: 38096106 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[80]
Cheong AJY, Tan BKJ, Teo YH et al.. “Obstructive Sleep Apnea and Lung Cancer: A Systematic Review and Meta-Analysis.” Annals of the American Thoracic Society (2022). PMID: 34792438 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[81]
Labarca G, Vena D, Hu WH et al.. “Sleep Apnea Physiological Burdens and Cardiovascular Morbidity and Mortality.” American journal of respiratory and critical care medicine (2023). PMID: 37418748 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[82]
Trzepizur W, Blanchard M, Ganem T et al.. “Sleep Apnea-Specific Hypoxic Burden, Symptom Subtypes, and Risk of Cardiovascular Events and All-Cause Mortality.” American journal of respiratory and critical care medicine (2022). PMID: 34648724 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[83]
Pack AI. “Advances in sleep-disordered breathing.” American journal of respiratory and critical care medicine (2005). PMID: 16284108 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors
[84]
Arzt M, Bradley TD. “Treatment of sleep apnea in heart failure.” American journal of respiratory and critical care medicine (2006). PMID: 16528015 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 8. Long-term and Definitive Management
[85]
Calhoun DA, Harding SM. “Sleep and hypertension.” Chest (2010). PMID: 20682533 ↗
L5OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[86]
Baffi CW, Wood L, Winnica D et al.. “Metabolic Syndrome and the Lung.” Chest (2016). PMID: 26836925 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications
[87]
Lal C, Strange C, Bachman D. “Neurocognitive impairment in obstructive sleep apnea.” Chest (2012). PMID: 22670023 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 10. Complications
[88]
Adesanya AO, Lee W, Greilich NB et al.. “Perioperative management of obstructive sleep apnea.” Chest (2010). PMID: 21138886 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 12. Special Populations & Pregnancy
[89]
Dyken ME, Im KB. “Obstructive sleep apnea and stroke.” Chest (2009). PMID: 19995768 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors
[90]
Tasali E, Mokhlesi B, Van Cauter E. “Obstructive sleep apnea and type 2 diabetes: interacting epidemics.” Chest (2008). PMID: 18252916 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[91]
Drager LF, Polotsky VY, Lorenzi-Filho G. “Obstructive sleep apnea: an emerging risk factor for atherosclerosis.” Chest (2011). PMID: 21813534 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 10. Complications
[92]
Sanchez-Cordero S, Lopez-Gonzalez R, Hermoza R et al.. “Systematic review of five-year outcomes after one-anastomosis gastric bypass.” Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery (2026). PMID: 42431778 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 10. Complications, 11. Prognosis and Natural History
[93]
Elagib T, Fan Y, Cornelis MA et al.. “Prevalence of Sleep-Disordered Breathing in Cleft-Affected Children: A Systematic Review and Meta-Analysis.” The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association (2026). PMID: 42429555 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[94]
Yam KJM, Lim CYJ, Gao EY et al.. “Artificial Intelligence Diagnosis of Obstructive Sleep Apnea Using Overnight Pulse Oximetry: A Systematic Review and Bayesian Meta-Analysis.” Journal of medical Internet research (2026). PMID: 42418449 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue
[95]
Kherallah K, Chung CS, Ghanshani R et al.. “The Impact of Chronic Spontaneous Urticaria on Sleep-A Systematic Review.” Dermatology and therapy (2026). PMID: 42366326 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management
[96]
Kuhle S, Urschitz MS. “Anti-inflammatory medications for obstructive sleep apnea in children.” The Cochrane database of systematic reviews (2011). PMID: 21249687 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 8. Long-term and Definitive Management, 12. Special Populations & Pregnancy
[97]
Sadeghi E, Kozlov M, Hasan N et al.. “Associations between psychiatric disorders and medication use, and retinal occlusion: a large-scale retrospective cohort study.” Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2026). PMID: 42371026 ↗
L3COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[98]
Thangjui S, Knutsen K, Hollowell B et al.. “Natural history and outcomes of post-operative atrial fibrillation after non-cardiac surgery: a clinically adjudicated single-center retrospective study.” Clinical research in cardiology : official journal of the German Cardiac Society (2026). PMID: 42370998 ↗
L3COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment, 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance
[99]
Jia Z, Xu Y, Zhang C et al.. “Transnasal Humidified Rapid-Insufflation Ventilatory Exchange versus Oropharyngeal Airway-Assisted Face-Mask Ventilation for Gastric Insufflation During Induction of General Anesthesia in Patients at High Risk for Obstructive Sleep Apnea.” Therapeutics and clinical risk management (2026). PMID: 42382179 ↗
L1TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[100]
Henney AE, Riley DR, Anson M et al.. “Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence.” Annals of the American Thoracic Society (2025). PMID: 40590655 ↗
L3OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[101]
Marin JM, Soriano JB, Marin-Oto M et al.. “Sleep-disordered Breathing in Patients with Chronic Obstructive Pulmonary Disease: Prevalence and Outcomes.” Annals of the American Thoracic Society (2025). PMID: 40208311 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[102]
Kundel V, Gans A, Lee JH et al.. “Heterogeneity of vascular inflammation in obstructive sleep apnea: effects of continuous positive airway pressure therapy.” Annals of the American Thoracic Society (2026). PMID: 41691476 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 11. Prognosis and Natural History
[103]
O'Donnell DE, Ciavaglia CE, Neder JA. “When obesity and chronic obstructive pulmonary disease collide. Physiological and clinical consequences.” Annals of the American Thoracic Society (2014). PMID: 24625243 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications, 11. Prognosis and Natural History
[104]
Xu L, Keenan BT, Wiemken AS et al.. “The Relationship between Upper Airway Anatomy and Obesity in Patients with Obstructive Sleep Apnea.” Annals of the American Thoracic Society (2025). PMID: 40523212 ↗
L4OTHERCited in: 3. Epidemiology, Etiology and Risk Factors
[105]
Kobayashi Frisk M, Bergqvist J, Svedmyr S et al.. “Comorbid Insomnia and Sleep Apnea Is Associated with Uncontrolled Hypertension in a Middle-aged Population.” Annals of the American Thoracic Society (2026). PMID: 40921000 ↗
L4OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[106]
Siranart N, Fangsaard P, Pajareya P et al.. “Improvement of Obesity-Related Comorbidities After Bariatric Procedures: A Network Meta-Analysis of Endoscopic Versus Surgical Interventions.” Digestive diseases and sciences (2026). PMID: 42423932 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification
[107]
Zhang KL, Wallon R, Laukaitis CM et al.. “Obstructive sleep apnea and CPAP efficacy in patients with Hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder: a case-control study.” Sleep & breathing = Schlaf & Atmung (2026). PMID: 42417930 ↗
L3CASE_CONTROLCited in: 3. Epidemiology, Etiology and Risk Factors
[108]
Liu X, Liu HL, Hu K. “[Interpretation and reflections on the 2025 American Academy of Sleep Medicine clinical practice guideline for the treatment of central sleep apnea in adults].” Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases (2026). PMID: 42373444 ↗
L5GUIDELINECited in: 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue
[109]
Guimarães KC, Drager LF, Genta PR et al.. “Effects of oropharyngeal exercises on patients with moderate obstructive sleep apnea syndrome.” American journal of respiratory and critical care medicine (2009). PMID: 19234106 ↗
L1RCTCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[110]
Hedner J, Stenlöf K, Zou D et al.. “A Randomized Controlled Clinical Trial Exploring Safety and Tolerability of Sulthiame in Sleep Apnea.” American journal of respiratory and critical care medicine (2022). PMID: 35202553 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[111]
Gagnadoux F, Pépin JL, Vielle B et al.. “Impact of Mandibular Advancement Therapy on Endothelial Function in Severe Obstructive Sleep Apnea.” American journal of respiratory and critical care medicine (2017). PMID: 28128967 ↗
L1RCTCited in: 4. Clinical Presentation
[112]
Drager LF, Bortolotto LA, Figueiredo AC et al.. “Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea.” American journal of respiratory and critical care medicine (2007). PMID: 17556718 ↗
L1RCTCited in: 4. Clinical Presentation
[113]
Tuomilehto HP, Seppä JM, Partinen MM et al.. “Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea.” American journal of respiratory and critical care medicine (2008). PMID: 19011153 ↗
L1RCTCited in: 4. Clinical Presentation
[114]
Campos-Rodriguez F, Queipo-Corona C, Carmona-Bernal C et al.. “Continuous Positive Airway Pressure Improves Quality of Life in Women with Obstructive Sleep Apnea. A Randomized Controlled Trial.” American journal of respiratory and critical care medicine (2016). PMID: 27181196 ↗
L1RCTCited in: 4. Clinical Presentation
[115]
Masa JF, Mokhlesi B, Benítez I et al.. “Echocardiographic Changes with Positive Airway Pressure Therapy in Obesity Hypoventilation Syndrome. Long-Term Pickwick Randomized Controlled Clinical Trial.” American journal of respiratory and critical care medicine (2020). PMID: 31682462 ↗
L1RCTCited in: 4. Clinical Presentation, 10. Complications
[116]
Cintra F, Tufik S, D'Almeida V et al.. “Cysteine: a potential biomarker for obstructive sleep apnea.” Chest (2010). PMID: 20651023 ↗
L3RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[117]
Moraes W, Poyares D, Sukys-Claudino L et al.. “Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study.” Chest (2008). PMID: 18198262 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management
[118]
McEvoy RD, Antic NA, Heeley E et al.. “CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea.” The New England journal of medicine (2016). PMID: 27571048 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[119]
Marcus CL, Moore RH, Rosen CL et al.. “A randomized trial of adenotonsillectomy for childhood sleep apnea.” The New England journal of medicine (2013). PMID: 23692173 ↗
L1RCTCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[120]
Bakker JP, Marshall NS. “Flexible pressure delivery modification of continuous positive airway pressure for obstructive sleep apnea does not improve compliance with therapy: systematic review and meta-analysis.” Chest (2010). PMID: 21193533 ↗
L1SR_OBSCited in: 4. Clinical Presentation, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[121]
Schmickl CN, Orr JE, Alex RM et al.. “Combination Drug Therapy with Acetazolamide, Eszopiclone ± Venlafaxine for Obstructive Sleep Apnea (RESCUE-Combo): A Randomized, Double-Blind, Placebo-controlled Clinical Trial.” Annals of the American Thoracic Society (2025). PMID: 39514000 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[122]
Aishah A, Loffler KA, Toson B et al.. “One Month Dosing of Atomoxetine plus Oxybutynin in Obstructive Sleep Apnea: A Randomized, Placebo-controlled Trial.” Annals of the American Thoracic Society (2023). PMID: 36538809 ↗
L1RCTCited in: 4. Clinical Presentation, History and Evolution of Treatment
[123]
Zuo C, Qin J, Wang Z et al.. “Effects of inspiratory muscle training on obstructive sleep apnea: a systematic review and meta-analysis.” Annals of the American Thoracic Society (2026). PMID: 41721779 ↗
L1SR_OBSCited in: 4. Clinical Presentation
[124]
Ozsancak A, D'Ambrosio C, Hill NS. “Nocturnal noninvasive ventilation.” Chest (2008). PMID: 18460530 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 10. Complications
[125]
Venkateshiah SB, Collop NA. “Sleep and sleep disorders in the hospital.” Chest (2012). PMID: 22553268 ↗
L5OTHERCited in: 4. Clinical Presentation, 11. Prognosis and Natural History
[126]
Xu Z, Cheuk DK, Lee SL. “Clinical evaluation in predicting childhood obstructive sleep apnea.” Chest (2006). PMID: 17166994 ↗
L4OTHERCited in: 4. Clinical Presentation, History and Evolution of Treatment
[127]
Kirkham EM, Ishman S, Garetz S et al.. “Progression of mild sleep-disordered breathing in children managed with watchful waiting.” Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine (2026). PMID: 42414790 ↗
L2RCTCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 12. Special Populations & Pregnancy
[128]
Abraham-Aggarwal K, Hung C, Chen X et al.. “Does treatment of nonsleepy OSA with CPAP therapy change CVD risk? A systematic review.” Sleep medicine (2026). PMID: 42349065 ↗
L1SR_OBSCited in: 4. Clinical Presentation
[129]
Izci-Balserak B, Zhu B, Gurubhagavatula I et al.. “A Screening Algorithm for Obstructive Sleep Apnea in Pregnancy.” Annals of the American Thoracic Society (2019). PMID: 31162952 ↗
L2OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications, 12. Special Populations & Pregnancy
[130]
Thornton JD, Dudley KA, Saeed GJ et al.. “Differences in Symptoms and Severity of Obstructive Sleep Apnea between Black and White Patients.” Annals of the American Thoracic Society (2022). PMID: 34242152 ↗
L2OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[131]
Ozden Sertcelik U, Turker M, Sertcelik A et al.. “The Association Between the STOP-Bang Score and the Integrated Pulmonary Index in Patients Undergoing Endobronchial Ultrasound with Sedation: The STOP OSA-IPI Cohort Study.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356047 ↗
L2COHORTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 12. Special Populations & Pregnancy
[132]
Hsu Y, Cheng WJ, Finnsson E et al.. “Endotypic trait responses to 12-month tirzepatide treatment for an obese patient with obstructive sleep apnea: a case report.” Obesity facts (2026). PMID: 42378200 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation
[133]
Ogundu PI, Bradley I, Ujari O et al.. “A 6-Year-Old Boy With Body Aches.” Pediatrics (2026). PMID: 42309516 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation
[134]
Naved SA, Khan M, Rasool S et al.. “Prophylactic bi-level non-invasive positive pressure ventilation during monitored anesthesia care for transfemoral TAVI in a morbidly obese patient with obstructive sleep apnea: a case report.” BMC anesthesiology (2026). PMID: 42260368 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation
[135]
Abideen ZU, Kolla BP, Bernard ME et al.. “Management of Central Disorders of Hypersomnolence in Pregnancy and Lactation.” Journal of primary care & community health (2026). PMID: 42212348 ↗
L5CASE_REPORTCited in: 4. Clinical Presentation
[136]
Dantas GL, Cavalcante MLC, Gomes EF et al.. “Clinical case-control study of the proprioceptive innervation of the pharynx in patients with obstructive sleep apnea.” Brazilian journal of otorhinolaryngology (2026). PMID: 42302464 ↗
L3CASE_CONTROLCited in: 4. Clinical Presentation
[137]
Shaw JE, Punjabi NM, Naughton MT et al.. “The Effect of Treatment of Obstructive Sleep Apnea on Glycemic Control in Type 2 Diabetes.” American journal of respiratory and critical care medicine (2016). PMID: 26926656 ↗
L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[138]
Zamarrón E, Jaureguizar A, García-Sánchez A et al.. “Continuous Positive Airway Pressure Effect on Albuminuria Progression in Patients with Obstructive Sleep Apnea and Diabetic Kidney Disease: A Randomized Clinical Trial.” American journal of respiratory and critical care medicine (2023). PMID: 36342964 ↗
L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications
[139]
Skomro RP, Gjevre J, Reid J et al.. “Outcomes of home-based diagnosis and treatment of obstructive sleep apnea.” Chest (2010). PMID: 20173052 ↗
L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management
[140]
Gottlieb DJ, Punjabi NM, Mehra R et al.. “CPAP versus oxygen in obstructive sleep apnea.” The New England journal of medicine (2014). PMID: 24918372 ↗
L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications, 11. Prognosis and Natural History
[141]
Rizzi CF, Cintra F, Risso T et al.. “Exercise capacity and obstructive sleep apnea in lean subjects.” Chest (2009). PMID: 19801583 ↗
L3TRIAL_NONRANDOMCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue
[142]
Van Ryswyk EM, Benitez ID, Sweetman AM et al.. “Primary versus Specialist Care for Obstructive Sleep Apnea: A Systematic Review and Individual-Participant Data-Level Meta-Analysis.” Annals of the American Thoracic Society (2022). PMID: 34524936 ↗
L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[143]
Kim JW, Lee K, Kim HJ et al.. “Predicting Obstructive Sleep Apnea Based on Computed Tomography Scans Using Deep Learning Models.” American journal of respiratory and critical care medicine (2024). PMID: 38471111 ↗
L3OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[144]
Sharma RA, Varga AW, Bubu OM et al.. “Obstructive Sleep Apnea Severity Affects Amyloid Burden in Cognitively Normal Elderly. A Longitudinal Study.” American journal of respiratory and critical care medicine (2018). PMID: 29125327 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 12. Special Populations & Pregnancy
[145]
Gervès-Pinquié C, Bailly S, Goupil F et al.. “Positive Airway Pressure Adherence, Mortality, and Cardiovascular Events in Patients with Sleep Apnea.” American journal of respiratory and critical care medicine (2022). PMID: 35816570 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[146]
Polotsky VY, Patil SP, Savransky V et al.. “Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity.” American journal of respiratory and critical care medicine (2008). PMID: 18990675 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[147]
Ayalon L, Ancoli-Israel S, Drummond SP. “Obstructive sleep apnea and age: a double insult to brain function?” American journal of respiratory and critical care medicine (2010). PMID: 20395556 ↗
L3OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[148]
Armoni Domany K, Hossain MM, Nava-Guerra L et al.. “Cardioventilatory Control in Preterm-born Children and the Risk of Obstructive Sleep Apnea.” American journal of respiratory and critical care medicine (2018). PMID: 29323933 ↗
L3OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[149]
Kendzerska T, Gershon AS, Povitz M et al.. “Polysomnographic Markers of Obstructive Sleep Apnea Severity and Cancer-related Mortality: A Large Retrospective Multicenter Clinical Cohort Study.” Annals of the American Thoracic Society (2022). PMID: 34788198 ↗
L2COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[150]
Patel NP, Ahmed M, Rosen I. “Split-night polysomnography.” Chest (2007). PMID: 17998369 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[151]
Cooksey JA, Balachandran JS. “Portable Monitoring for the Diagnosis of OSA.” Chest (2016). PMID: 26539918 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[152]
Montesi SB, Bajwa EK, Malhotra A. “Biomarkers of sleep apnea.” Chest (2012). PMID: 22796846 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[153]
Simon S, Collop N. “Latest advances in sleep medicine: obstructive sleep apnea.” Chest (2012). PMID: 23208337 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification
[154]
Kaw R, Michota F, Jaffer A et al.. “Unrecognized sleep apnea in the surgical patient: implications for the perioperative setting.” Chest (2006). PMID: 16424433 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 12. Special Populations & Pregnancy
[155]
Lancaster LH, Mason WR, Parnell JA et al.. “Obstructive sleep apnea is common in idiopathic pulmonary fibrosis.” Chest (2009). PMID: 19567497 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[156]
Ahmed M, Patel NP, Rosen I. “Portable monitors in the diagnosis of obstructive sleep apnea.” Chest (2007). PMID: 17998370 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[157]
Flum DR, Belle SH, King WC et al.. “Perioperative safety in the longitudinal assessment of bariatric surgery.” The New England journal of medicine (2009). PMID: 19641201 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[158]
Baron KG, Alcántara C, López I et al.. “Protocol for Nuestro Sueño: A randomized trial of a couples-based intervention to improve PAP adherence and sleep health among Hispanic patients beginning positive airway pressure (PAP) and their partners.” Sleep medicine (2026). PMID: 42176392 ↗
L5TRIAL_NONRANDOMCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[159]
Zafar A, Roman U, Haseeb A et al.. “Reliability of Home Sleep Apnea Test as a Diagnostic Modality in Children With Obstructive Sleep Apnea- a Systematic Review.” Pediatric pulmonology (2026). PMID: 42165382 ↗
L2SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, 10. Complications, 12. Special Populations & Pregnancy
[160]
Sung J, Chang R, Chen SN et al.. “Obstructive Sleep Apnea and Risk for Thromboembolic Complication Among Patients With Polycystic Ovary Syndrome: A Retrospective Cohort Study.” BJOG : an international journal of obstetrics and gynaecology (2026). PMID: 42248807 ↗
L2COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management
[161]
Nishida T, Mittal R, Weinreb RN et al.. “Positive Airway Pressure and Long-Term Glaucoma Risk in Obstructive Sleep Apnea: A Cohort Study.” Ophthalmology. Glaucoma (2026). PMID: 42235822 ↗
L2COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management
[162]
Pépin JL, Herquelot E, Denis H et al.. “Health Trajectories around Noninvasive Ventilation Initiation for Obesity Hypoventilation Syndrome.” Annals of the American Thoracic Society (2025). PMID: 40587365 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management
[163]
Chang JR, Akemokwe FM, Marangu DM et al.. “Obstructive Sleep Apnea Awareness among Primary Care Physicians in Africa.” Annals of the American Thoracic Society (2020). PMID: 31580702 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 12. Special Populations & Pregnancy
[164]
Thomas S, Tharrington SG, Patel A et al.. “Racial and Ethnic Disparities in the Diagnosis and Treatment of Obstructive Sleep Apnea: A Systematic Review.” International journal of environmental research and public health (2026). PMID: 42196707 ↗
L2SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[165]
Chiang JK, Kao HH, Chiang PH et al.. “Vitamin D Deficiency Is Associated with a Higher 5-Year Risk of Obstructive Sleep Apnea and CPAP Use in Older Adults: An Anchor-Based Network Meta-Analysis.” Medicina (Kaunas, Lithuania) (2026). PMID: 42195188 ↗
L2SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[166]
Alahmadi HI. “Nocturnal hypoxemic burden in obesity hypoventilation syndrome compared to obstructive sleep apnea: a case-control study.” Sleep & breathing = Schlaf & Atmung (2026). PMID: 42366321 ↗
L3CASE_CONTROLCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue
[167]
Lavoie V, Pichard S, Bouchereau J et al.. “Pediatric sleep-disordered breathing in Pompe disease in the era of enzyme replacement therapy: A retrospective cohort study.” Molecular genetics and metabolism (2026). PMID: 42322896 ↗
L4COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[168]
Taranto-Montemurro L, Messineo L, Sands SA et al.. “The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial.” American journal of respiratory and critical care medicine (2019). PMID: 30395486 ↗
L1RCTCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[169]
Xu H, Liu Y, Li C et al.. “Effects of Continuous Positive Airway Pressure on Neuroimaging Biomarkers and Cognition in Adult Obstructive Sleep Apnea: A Randomized Controlled Trial.” American journal of respiratory and critical care medicine (2025). PMID: 39998447 ↗
L1RCTCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[170]
Strollo PJ, Farkas R, Taranto-Montemurro L et al.. “Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy).” American journal of respiratory and critical care medicine (2026). PMID: 42148495 ↗
L1RCTCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[171]
Messineo L, Sands SA, Labarca G. “Hypnotics on Obstructive Sleep Apnea Severity and Endotypes: A Systematic Review and Meta-Analysis.” American journal of respiratory and critical care medicine (2024). PMID: 39042859 ↗
L1SR_OBSCited in: 6. Severity, Staging and Risk Stratification
[172]
Strollo PJ, Soose RJ, Maurer JT et al.. “Upper-airway stimulation for obstructive sleep apnea.” The New England journal of medicine (2014). PMID: 24401051 ↗
L4RCTCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[173]
Romero-Corral A, Caples SM, Lopez-Jimenez F et al.. “Interactions between obesity and obstructive sleep apnea: implications for treatment.” Chest (2010). PMID: 20202954 ↗
L5REVIEW_NARRATIVECited in: 6. Severity, Staging and Risk Stratification
[174]
Suen C, Ryan CM, Mubashir T et al.. “Sleep Study and Oximetry Parameters for Predicting Postoperative Complications in Patients With OSA.” Chest (2018). PMID: 30359618 ↗
L5REVIEW_NARRATIVECited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[175]
Azzopardi M, Parsons R, Cadby G et al.. “Identifying Risk of Postoperative Cardiorespiratory Complications in OSA.” Chest (2024). PMID: 39134145 ↗
L2OTHERCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[176]
Rosa CFA, de Paula Soares CF, Cahali MB. “Which nocturnal hypoxemia parameters are associated with ambulatory blood pressure monitoring in adults with obstructive sleep apnea? A systematic review.” Sleep & breathing = Schlaf & Atmung (2026). PMID: 42397627 ↗
L5SR_OBSCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue
[177]
Chen D, Zhang X, Liu C et al.. “Correction: Association between obstructive sleep apnea syndrome and metabolic syndrome: a severity-stratified meta-analysis.” Frontiers in medicine (2026). PMID: 42422827 ↗
L2SR_OBSCited in: 6. Severity, Staging and Risk Stratification
[178]
Cai P, Li B, Li Y et al.. “Association of peripheral NLRP3 inflammasome activation with prevalent and incident chronic kidney disease in patients with obstructive sleep apnea: a prospective study.” Sleep & breathing = Schlaf & Atmung (2026). PMID: 42377775 ↗
L2COHORTCited in: 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[179]
Hang LW, Finnsson E, Ágústsson JS et al.. “Association of Endotypic Traits and Their Interaction With Severity of Obstructive Sleep Apnea.” Respirology (Carlton, Vic.) (2026). PMID: 41813440 ↗
L2OTHERCited in: 6. Severity, Staging and Risk Stratification
[180]
Vena D, Gell L, Messineo L et al.. “Physiological Determinants of Snore Loudness.” Annals of the American Thoracic Society (2024). PMID: 37879037 ↗
L4OTHERCited in: 6. Severity, Staging and Risk Stratification
[181]
Schweitzer PK, Taranto-Montemurro L, Ojile JM et al.. “The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial.” American journal of respiratory and critical care medicine (2023). PMID: 37812772 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[182]
Schwartz AR, Jacobowitz O, Mickelson SA et al.. “Three-Year Outcomes of Proximal Hypoglossal Nerve Stimulation in OSA.” Chest (2026). PMID: 41690459 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[183]
Khayat RN, Abraham WT, Patt B et al.. “In-hospital treatment of obstructive sleep apnea during decompensation of heart failure.” Chest (2009). PMID: 19567491 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[184]
Schweitzer PK, Mayer G, Rosenberg R et al.. “Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment.” Chest (2021). PMID: 33631141 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management
[185]
Imadojemu VA, Mawji Z, Kunselman A et al.. “Sympathetic chemoreflex responses in obstructive sleep apnea and effects of continuous positive airway pressure therapy.” Chest (2007). PMID: 17494791 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue
[186]
Chirinos JA, Gurubhagavatula I, Teff K et al.. “CPAP, weight loss, or both for obstructive sleep apnea.” The New England journal of medicine (2014). PMID: 24918371 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[187]
Messineo L, Gell L, Calianese N et al.. “Effect of Pimavanserin on the Respiratory Arousal Threshold from Sleep: A Randomized Trial.” Annals of the American Thoracic Society (2022). PMID: 35947827 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[188]
Christopher KL, Schwartz MD. “Transtracheal oxygen therapy.” Chest (2011). PMID: 21285058 ↗
L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
[189]
Stephens TN, Wang Y, Guo J et al.. “Evaluation of a sleep sound analysis smartphone app for home obstructive sleep apnea screening among community-dwelling Chinese adults with hypertension.” Sleep & breathing = Schlaf & Atmung (2026). PMID: 42412159 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[190]
Jiang Y, Wang Z, Wen H et al.. “Comparison of esketamine combined with dexmedetomidine versus propofol combined with midazolam on drug-induced sleep endoscopy: a randomized controlled trial.” BMC anesthesiology (2026). PMID: 42288726 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[191]
Tong BK, Stewart GM, Dissanayake H et al.. “Feasibility and impact of personalized therapy for obstructive sleep apnea in patients with acute coronary syndrome: a pilot randomized controlled trial.” Pilot and feasibility studies (2026). PMID: 42243889 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[192]
Zhao M, Wang L, Qin B et al.. “Efficacy and safety of atomoxetine combination therapy for obstructive sleep apnea: A meta-analysis of randomized placebo-controlled trials.” Sleep medicine (2026). PMID: 42269187 ↗
L1SR_OBSCited in: 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[193]
Attaway AH, Mehra R, Zein JG et al.. “Nocturnal Hypoxemia Is Associated with Sarcopenia in Patients with Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2024). PMID: 38843487 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue
[194]
Gomes B, Esquinas AM, Alwajeeh FN. “Non-invasive ventilation in severe acute respiratory failure complicating Madelung's disease: a case series and management review.” Frontiers in medicine (2026). PMID: 42328573 ↗
L4CASE_REPORTCited in: 7. Acute Management and Exacerbation Rescue
[195]
Parthasarathy S, Wendel C, Grandner MA et al.. “Peer-Driven Intervention for Care Coordination and Adherence Promotion for Obstructive Sleep Apnea: A Randomized, Parallel-Group Clinical Trial.” American journal of respiratory and critical care medicine (2025). PMID: 39441133 ↗
L1RCTCited in: 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[196]
Zinchuk AV, Chu JH, Liang J et al.. “Physiological Traits and Adherence to Sleep Apnea Therapy in Individuals with Coronary Artery Disease.” American journal of respiratory and critical care medicine (2021). PMID: 34156917 ↗
L2RCTCited in: 8. Long-term and Definitive Management
[197]
Strollo PJ, Hedner J, Collop N et al.. “Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study.” Chest (2018). PMID: 30471270 ↗
L1RCTCited in: 8. Long-term and Definitive Management
[198]
de Oliveira ACT, Martinez D, Vasconcelos LFT et al.. “Diagnosis of obstructive sleep apnea syndrome and its outcomes with home portable monitoring.” Chest (2009). PMID: 19201709 ↗
L2RCTCited in: 8. Long-term and Definitive Management
[199]
Coruzzi P, Gualerzi M, Bernkopf E et al.. “Autonomic cardiac modulation in obstructive sleep apnea: effect of an oral jaw-positioning appliance.” Chest (2006). PMID: 17099011 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term and Definitive Management
[200]
Lorenzi-Filho G, Cruz FCSG, Queiróz DBC et al.. “Effects of Continuous Positive Airway Pressure on Central and Peripheral Blood Pressure in Patients with Uncontrolled Hypertension and Obstructive Sleep Apnea: The Randomized Controlled MORPHEOS Clinical Trial.” Annals of the American Thoracic Society (2025). PMID: 39879540 ↗
L1RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment
[201]
Tsou PY, Alex RM, Redline S et al.. “Pathophysiological Traits in Pediatric Obstructive Sleep Apnea. Associations with Patient Characteristics and Responses to Therapy: A Secondary Analysis of the CHAT Clinical Trial.” Annals of the American Thoracic Society (2025). PMID: 40720163 ↗
L2RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment, 12. Special Populations & Pregnancy
[202]
Shah R, Patel N, Emin M et al.. “Statins Restore Endothelial Protection against Complement Activity in Obstructive Sleep Apnea: A Randomized Clinical Trial.” Annals of the American Thoracic Society (2023). PMID: 36912897 ↗
L1RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment
[203]
Murase K, Tanizawa K, Minami T et al.. “A Randomized Controlled Trial of Telemedicine for Long-Term Sleep Apnea Continuous Positive Airway Pressure Management.” Annals of the American Thoracic Society (2020). PMID: 31689141 ↗
L1RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment
[204]
Fridriksson B, Berndtson M, Hamnered H et al.. “Beneficial Effects of Early Intervention Telemedicine-based Follow-Up in Sleep Apnea: A Randomized Controlled Multicenter Trial.” Annals of the American Thoracic Society (2023). PMID: 37463309 ↗
L1RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment
[205]
Lichtblau M, Schwarz EI, Ulrich T et al.. “Effect of an Overnight Stay at 2,500 Meters on Nocturnal Hypoxemia and Sleep-disordered Breathing in Patients with Pulmonary Vascular Disease: A Randomized Clinical Trial.” Annals of the American Thoracic Society (2025). PMID: 40085143 ↗
L1RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications
[206]
Chowdhuri S, Quan SF, Almeida F et al.. “An Official American Thoracic Society Research Statement: Impact of Mild Obstructive Sleep Apnea in Adults.” American journal of respiratory and critical care medicine (2016). PMID: 27128710 ↗
L1REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management, 10. Complications
[207]
Cade BE, Chen H, Stilp AM et al.. “Genetic Associations with Obstructive Sleep Apnea Traits in Hispanic/Latino Americans.” American journal of respiratory and critical care medicine (2016). PMID: 26977737 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[208]
Efune PN, Nakonezny PA, Pinales P et al.. “Effect of neuromuscular blockade on opioid consumption in high-risk children undergoing adenotonsillectomy: A randomized-controlled trial.” Journal of clinical anesthesia (2026). PMID: 42107449 ↗
L1RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications
[209]
Kung SC, Shen YC, Wang HM et al.. “Investigating the effects of CPAP/BiPAP therapy on cognitive function and reaction time in patients with obesity hypoventilation syndrome.” Respiratory physiology & neurobiology (2026). PMID: 42150628 ↗
L1RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment
[210]
Gupta AK, Narula V, Sharma S et al.. “Comparative effectiveness of Mandibular advancement devices and Continuous positive airway pressure in adults with obstructive sleep Apnea: A systematic review and meta-analysis.” Sleep medicine (2026). PMID: 42287974 ↗
L1SR_OBSCited in: 8. Long-term and Definitive Management
[211]
Moffa A, Nardelli D, Iafrati F et al.. “What do patients want for their sleep apnea? A systematic review of treatment choice and preference drivers.” Sleep & breathing = Schlaf & Atmung (2026). PMID: 42274931 ↗
L2SR_OBSCited in: 8. Long-term and Definitive Management
[212]
Zhang Y, Wang J, Zhang J et al.. “Comparative efficacy of positive airway pressure-based combination therapy in comorbid insomnia and sleep apnea: A systematic review and network meta-analysis.” Sleep medicine reviews (2026). PMID: 42107468 ↗
L1SR_OBSCited in: 8. Long-term and Definitive Management
[213]
Tseng JJ, Wang JJ, Lin MC et al.. “Long-term health outcomes of pediatric obstructive sleep apnea: A 10-year multicenter cohort study.” Sleep medicine (2026). PMID: 42127725 ↗
L2COHORTCited in: 8. Long-term and Definitive Management, 12. Special Populations & Pregnancy
[214]
Cunningham TJ, Kishore D, Guo M et al.. “The Effect of Obstructive Sleep Apnea on Sleep-dependent Emotional Memory Consolidation.” Annals of the American Thoracic Society (2023). PMID: 36250951 ↗
L4OTHERCited in: 8. Long-term and Definitive Management
[215]
Berry RB, Kouchi K, Bower J et al.. “Triazolam in patients with obstructive sleep apnea.” American journal of respiratory and critical care medicine (1995). PMID: 7842205 ↗
L1RCTCited in: History and Evolution of Treatment
[216]
Mulloy E, McNicholas WT. “Theophylline in obstructive sleep apnea. A double-blind evaluation.” Chest (1992). PMID: 1541143 ↗
L1RCTCited in: History and Evolution of Treatment
[217]
Collop NA. “Medroxyprogesterone acetate and ethanol-induced exacerbation of obstructive sleep apnea.” Chest (1994). PMID: 8082361 ↗
L1RCTCited in: History and Evolution of Treatment
[218]
Brownell LG, West P, Sweatman P et al.. “Protriptyline in obstructive sleep apnea: a double-blind trial.” The New England journal of medicine (1982). PMID: 6750396 ↗
L1RCTCited in: History and Evolution of Treatment
[219]
Simantirakis EN, Schiza SE, Chrysostomakis SI et al.. “Atrial overdrive pacing for the obstructive sleep apnea-hypopnea syndrome.” The New England journal of medicine (2005). PMID: 16354893 ↗
L2RCTCited in: History and Evolution of Treatment
[220]
Garrigue S, Bordier P, Jaïs P et al.. “Benefit of atrial pacing in sleep apnea syndrome.” The New England journal of medicine (2002). PMID: 11832528 ↗
L2RCTCited in: History and Evolution of Treatment
[221]
Kaneko Y, Floras JS, Usui K et al.. “Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea.” The New England journal of medicine (2003). PMID: 12660387 ↗
L1RCTCited in: History and Evolution of Treatment
[222]
Brown KM, Malow BA. “Pediatric Insomnia.” Chest (2016). PMID: 26378738 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, 12. Special Populations & Pregnancy
[223]
Fernández-Barriales M, López de Luzuriaga M, Lafuente-Ibáñez de Mendoza I et al.. “Controlled Prospective Evidence of Rapid Maxillary Expansion Efficacy in Pediatric Obstructive Sleep Apnea: A Systematic Review Update.” Journal of clinical medicine (2026). PMID: 42074778 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[224]
Mendelson WB. “Sleepiness and hypertension in obstructive sleep apnea.” Chest (1992). PMID: 1555460 ↗
L2OTHERCited in: History and Evolution of Treatment
[225]
Sorajja D, Gami AS, Somers VK et al.. “Independent association between obstructive sleep apnea and subclinical coronary artery disease.” Chest (2008). PMID: 18263678 ↗
L2OTHERCited in: History and Evolution of Treatment
[226]
Guilleminault C, Motta J, Mihm F et al.. “Obstructive sleep apnea and cardiac index.” Chest (1986). PMID: 3948544 ↗
L4OTHERCited in: History and Evolution of Treatment
[227]
Kaw R, Pasupuleti V, Walker E et al.. “Postoperative complications in patients with obstructive sleep apnea.” Chest (2011). PMID: 21868464 ↗
L2OTHERCited in: History and Evolution of Treatment, 12. Special Populations & Pregnancy
[228]
Fank F, Artismo RS, Rocha AR et al.. “Effects of combined exercise and sleep hygiene on obstructive sleep apnea severity in older adults: a randomized controlled trial.” Sleep medicine (2026). PMID: 42025100 ↗
L1RCTCited in: History and Evolution of Treatment
[229]
Malhotra A, Schwartz AR, Lovett E et al.. “Proximal Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea in the OSPREY Study : A Randomized Controlled Trial.” Annals of internal medicine (2026). PMID: 42008810 ↗
L1RCTCited in: History and Evolution of Treatment
[230]
Peker Y, Glantz H, Thunström E et al.. “CPAP does not modify exercise-derived autonomic responses in nonsleepy patients with coronary artery disease and obstructive sleep apnea.” Sleep medicine (2026). PMID: 41980537 ↗
L1RCTCited in: History and Evolution of Treatment
[231]
Andrews ND, El Ahdab J, Pascoe M et al.. “What's leak got to do with it? Association of mask leak and positive airway pressure adherence from the homepap study.” Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine (2026). PMID: 41963755 ↗
L1RCTCited in: History and Evolution of Treatment
[232]
Al-Rawi NH, Elsayed W, Al-Bayati SF et al.. “Artificial intelligence applications in CBCT-based assessment of craniofacial airway volume and shape in sleep-disordered breathing: a systematic review.” PeerJ (2026). PMID: 42328666 ↗
L2SR_OBSCited in: History and Evolution of Treatment
[233]
Birnbaum S. “Pulse oximetry: identifying its applications, coding, and reimbursement.” Chest (2009). PMID: 19265093 ↗
L5OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[234]
Shen H, Xu Y, Zhang Y et al.. “Efficacy of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease and obstructive sleep apnea; a randomized controlled trial.” Journal of rehabilitation medicine (2024). PMID: 39318173 ↗
L1RCTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[235]
Erturk N, Celik A, Kahraman Yaman S et al.. “Expiratory muscle strength training reduces oxidative stress and systemic inflammation in men with obstructive sleep apnea syndrome: a double-blinded, randomized parallel trial.” Sleep (2024). PMID: 39297486 ↗
L1RCTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[236]
Neumannova K, Hobzova M, Sova M et al.. “Pulmonary rehabilitation and oropharyngeal exercises as an adjunct therapy in obstructive sleep apnea: a randomized controlled trial.” Sleep medicine (2018). PMID: 30292081 ↗
L1RCTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[237]
Jurado-García A, Molina-Recio G, Feu-Collado N et al.. “Effect of a Graduated Walking Program on the Severity of Obstructive Sleep Apnea Syndrome. A Randomized Clinical Trial.” International journal of environmental research and public health (2020). PMID: 32878112 ↗
L1RCTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[238]
Soler X, Gaio E, Powell FL et al.. “High Prevalence of Obstructive Sleep Apnea in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2015). PMID: 25871443 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[239]
Gupta S, Kumar R, Gupta NK et al.. “Effect of high flow nasal cannula versus conventional nasal cannula oxygen therapy in patients undergoing endobronchial ultrasound-guided transbronchial needle aspiration.” Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace (2025). PMID: 39968686 ↗
L1RCTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[240]
Arwas N, Goldbart A, Aviram M et al.. “Flexible bronchoscopy in pediatric patients with Down syndrome: A case-control study of the indications, findings, and complications.” Pediatric pulmonology (2023). PMID: 36811243 ↗
L3CASE_CONTROLCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[241]
Lima E, Nakamura MAM, Genta PR et al.. “Improving Airways Patency and Ventilation Through Optimal Positive Pressure Identified by Noninvasive Mechanical Ventilation Titration in Mounier-Kuhn Syndrome: Protocol for an Interventional, Open-Label, Single-Arm Clinical Trial.” JMIR research protocols (2020). PMID: 32795996 ↗
L5TRIAL_NONRANDOMCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[242]
Commesso EA, Paoletti MF, Kezirian EJ. “Hypoglossal Nerve Stimulation Respiratory Lead Migration: MAUDE Database Review and Case Report.” OTO open (2025). PMID: 40511388 ↗
L4CASE_REPORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[243]
Zhang Q, Qin Z, Hu R et al.. “A rare early-onset neonatal case of Birk-Barel syndrome presenting severe obstructive sleep apnea: a case report.” Frontiers in medicine (2023). PMID: 37358997 ↗
L4CASE_REPORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[244]
Liang H, Hou Y, Wei H et al.. “Supraglottic jet oxygenation and ventilation assisted fiberoptic intubation in a paralyzed patient with morbid obesity and obstructive sleep apnea: a case report.” BMC anesthesiology (2019). PMID: 30894124 ↗
L4CASE_REPORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[245]
Berger K, Braverman G, Siltumens A et al.. “Care of the Patient with Interstitial Lung Disease Perioperatively.” Current rheumatology reports (2026). PMID: 42059971 ↗
L5REVIEW_NARRATIVECited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[246]
De Jong A, Molinari N, Terzi N et al.. “Early identification of patients at risk for difficult intubation in the intensive care unit: development and validation of the MACOCHA score in a multicenter cohort study.” American journal of respiratory and critical care medicine (2013). PMID: 23348979 ↗
L2TRIAL_NONRANDOMCited in: 10. Complications
[247]
Ulrich S, Fischler M, Speich R et al.. “Sleep-related breathing disorders in patients with pulmonary hypertension.” Chest (2008). PMID: 18339776 ↗
L4TRIAL_NONRANDOMCited in: 10. Complications
[248]
García-Sánchez A, Villalaín-Rodes I, Jaureguizar A et al.. “Continuous Positive Airway Pressure Effect on Progression of Retinal Disease in Patients with Sleep Apnea and Nonproliferative Diabetic Retinopathy: A Randomized Clinical Trial.” Annals of the American Thoracic Society (2024). PMID: 37793101 ↗
L1RCTCited in: 10. Complications
[249]
Gozal D, Kheirandish-Gozal L. “Cardiovascular morbidity in obstructive sleep apnea: oxidative stress, inflammation, and much more.” American journal of respiratory and critical care medicine (2007). PMID: 17975198 ↗
L5REVIEW_NARRATIVECited in: 10. Complications
[250]
Mason RH, Ruegg G, Perkins J et al.. “Obstructive sleep apnea in patients with abdominal aortic aneurysms: highly prevalent and associated with aneurysm expansion.” American journal of respiratory and critical care medicine (2010). PMID: 20622036 ↗
L3OTHERCited in: 10. Complications, 13. Prevention, Screening & Surveillance
[251]
Lagravinese G, Santacesaria P, Castellana G et al.. “EEG patterns and cognitive outcomes in chronic respiratory disorders: a systematic review.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2026). PMID: 42349048 ↗
L2SR_OBSCited in: 10. Complications
[252]
Rebibo L, Tropeano AI, Vilfaillot A et al.. “Same-day discharge sleeve gastrectomy in France on the last decade: a nationwide cohort study on safety and patient selection.” Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery (2026). PMID: 42270484 ↗
L2COHORTCited in: 10. Complications, 11. Prognosis and Natural History
[253]
Li Y, Zhang R, Li N et al.. “The impact of dexmedetomidine on postoperative delirium in obstructive sleep apnea patients (DPOD-OSA): study protocol for a prospective randomized controlled trial.” Trials (2026). PMID: 42144647 ↗
L5TRIAL_NONRANDOMCited in: 10. Complications
[254]
Collaco JM, McGrath-Morrow SA. “Respiratory Phenotypes for Preterm Infants, Children, and Adults: Bronchopulmonary Dysplasia and More.” Annals of the American Thoracic Society (2018). PMID: 29328889 ↗
L5REVIEW_NARRATIVECited in: 10. Complications, 12. Special Populations & Pregnancy
[255]
May AM. “Sleep-disordered Breathing and Inpatient Outcomes in Nonsurgical Patients: Analysis of the Nationwide Inpatient Cohort.” Annals of the American Thoracic Society (2023). PMID: 37748082 ↗
L2OTHERCited in: 10. Complications
[256]
Manthous CA, Mokhlesi B. “Avoiding Management Errors in Patients with Obesity Hypoventilation Syndrome.” Annals of the American Thoracic Society (2016). PMID: 26512908 ↗
L5OTHERCited in: 10. Complications
[257]
Ayas NT, Laratta CR, Coleman JM et al.. “Knowledge Gaps in the Perioperative Management of Adults with Obstructive Sleep Apnea and Obesity Hypoventilation Syndrome. An Official American Thoracic Society Workshop Report.” Annals of the American Thoracic Society (2018). PMID: 29388810 ↗
L5OTHERCited in: 10. Complications
[258]
Pepin JL, Herquelot E, Denis H et al.. “Mortality impact of long-term home non-invasive ventilation in COPD patients with versus without obstructive sleep apnea.” Annals of the American Thoracic Society (2026). PMID: 41915562 ↗
L2OTHERCited in: 10. Complications
[259]
Fitriana F, Hariri F, Sng JHT et al.. “Midface Advancement Surgery and Its Effects on Upper Airway Function and Obstructive Sleep Apnea Status in Children With Syndromic Craniosynostosis: A Systematic Review.” The Journal of craniofacial surgery (2026). PMID: 42228493 ↗
L5SR_OBSCited in: 10. Complications, 12. Special Populations & Pregnancy
[260]
Cakmak Demir S, Batman A, Yazici D et al.. “Association of High-Risk Obstructive Sleep Apnea with Microvascular Complications in Adults with Type 1 Diabetes Mellitus: A Case-Control Study.” Journal of clinical medicine (2026). PMID: 42074704 ↗
L3CASE_CONTROLCited in: 10. Complications
[261]
Moioli D, Cesana G, Ciccarese F et al.. “Single Anastomosis Sleeve Ileal Bypass Could Be the Future of Redo Surgery? A Single-Center Cohort Study.” Journal of laparoendoscopic & advanced surgical techniques. Part A (2026). PMID: 42120341 ↗
L2COHORTCited in: 10. Complications
[262]
Gonçalves SC, Martinez D, Gus M et al.. “Obstructive sleep apnea and resistant hypertension: a case-control study.” Chest (2007). PMID: 18079220 ↗
L3CASE_CONTROLCited in: 11. Prognosis and Natural History
[263]
Bhattacharjee R, Kheirandish-Gozal L, Spruyt K et al.. “Adenotonsillectomy outcomes in treatment of obstructive sleep apnea in children: a multicenter retrospective study.” American journal of respiratory and critical care medicine (2010). PMID: 20448096 ↗
L2COHORTCited in: 12. Special Populations & Pregnancy
[264]
Kheirandish-Gozal L, Bandla HP, Gozal D. “Montelukast for Children with Obstructive Sleep Apnea: Results of a Double-Blind, Randomized, Placebo-Controlled Trial.” Annals of the American Thoracic Society (2016). PMID: 27439031 ↗
L1RCTCited in: 12. Special Populations & Pregnancy
[265]
Panyarath P, Goldscher N, Pamidi S et al.. “Positive Airway Pressure Treatment of Obstructive Sleep Apnea-Hypopnea in Hypertensive Disorders of Pregnancy: A Pilot Randomized Proof-of-Concept Clinical Trial.” Annals of the American Thoracic Society (2024). PMID: 38252423 ↗
L1RCTCited in: 12. Special Populations & Pregnancy
[266]
Ievers-Landis CE, Redline S. “Pediatric sleep apnea: implications of the epidemic of childhood overweight.” American journal of respiratory and critical care medicine (2006). PMID: 17158283 ↗
L5REVIEW_NARRATIVECited in: 12. Special Populations & Pregnancy
[267]
Hornero R, Kheirandish-Gozal L, Gutiérrez-Tobal GC et al.. “Nocturnal Oximetry-based Evaluation of Habitually Snoring Children.” American journal of respiratory and critical care medicine (2017). PMID: 28759260 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[268]
Gozal D, Capdevila OS, Kheirandish-Gozal L. “Metabolic alterations and systemic inflammation in obstructive sleep apnea among nonobese and obese prepubertal children.” American journal of respiratory and critical care medicine (2008). PMID: 18276939 ↗
L3OTHERCited in: 12. Special Populations & Pregnancy
[269]
Kheirandish-Gozal L, Bhattacharjee R, Kim J et al.. “Endothelial progenitor cells and vascular dysfunction in children with obstructive sleep apnea.” American journal of respiratory and critical care medicine (2010). PMID: 20203242 ↗
L3OTHERCited in: 12. Special Populations & Pregnancy
[270]
Tarasiuk A, Greenberg-Dotan S, Simon-Tuval T et al.. “Elevated morbidity and health care use in children with obstructive sleep apnea syndrome.” American journal of respiratory and critical care medicine (2006). PMID: 17038661 ↗
L3OTHERCited in: 12. Special Populations & Pregnancy
[271]
Kim J, Bhattacharjee R, Khalyfa A et al.. “DNA methylation in inflammatory genes among children with obstructive sleep apnea.” American journal of respiratory and critical care medicine (2011). PMID: 22077067 ↗
L3OTHERCited in: 12. Special Populations & Pregnancy
[272]
Khalyfa A, Gharib SA, Kim J et al.. “Transcriptomic analysis identifies phosphatases as novel targets for adenotonsillar hypertrophy of pediatric obstructive sleep apnea.” American journal of respiratory and critical care medicine (2010). PMID: 20093640 ↗
L3OTHERCited in: 12. Special Populations & Pregnancy
[273]
Dayyat E, Kheirandish-Gozal L, Sans Capdevila O et al.. “Obstructive sleep apnea in children: relative contributions of body mass index and adenotonsillar hypertrophy.” Chest (2009). PMID: 19225059 ↗
L3OTHERCited in: 12. Special Populations & Pregnancy
[274]
Verhulst SL, Aerts L, Jacobs S et al.. “Sleep-disordered breathing, obesity, and airway inflammation in children and adolescents.” Chest (2008). PMID: 18689597 ↗
L3OTHERCited in: 12. Special Populations & Pregnancy
[275]
Sharma SK, Kumpawat S, Banga A et al.. “Prevalence and risk factors of obstructive sleep apnea syndrome in a population of Delhi, India.” Chest (2006). PMID: 16840395 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[276]
Yao J, Jin T, Huang A et al.. “Tympanocentesis or not? A prospective cohort study for obstructive sleep apnea children in conjunction with asymptomatic otitis media with effusion.” Frontiers in medicine (2026). PMID: 42205832 ↗
L2COHORTCited in: 12. Special Populations & Pregnancy
[277]
Qin J, Zhang J, Ge M et al.. “Associations of Preoperative HMGB-1 and Systemic Immune-Inflammation Index with Short-Term Behavioral Improvement After Adenotonsillectomy in Children with OSAHS.” Journal of inflammation research (2026). PMID: 42199628 ↗
L2TRIAL_NONRANDOMCited in: 12. Special Populations & Pregnancy
[278]
Wang R, Dong Y, Weng J et al.. “Associations among Neighborhood, Race, and Sleep Apnea Severity in Children. A Six-City Analysis.” Annals of the American Thoracic Society (2017). PMID: 27768852 ↗
L3OTHERCited in: 12. Special Populations & Pregnancy
[279]
Izci Balserak B, Pien GW, Prasad B et al.. “Obstructive Sleep Apnea Is Associated with Newly Diagnosed Gestational Diabetes Mellitus.” Annals of the American Thoracic Society (2020). PMID: 32040334 ↗
L3OTHERCited in: 12. Special Populations & Pregnancy
[280]
Goswami U, Ensrud KE, Paudel ML et al.. “Vitamin D Concentrations and Obstructive Sleep Apnea in a Multicenter Cohort of Older Males.” Annals of the American Thoracic Society (2016). PMID: 26845389 ↗
L4OTHERCited in: 12. Special Populations & Pregnancy
[281]
Li Q, Zhong Q, Kong X et al.. “Allergic rhinitis in children in relation to sleep breathing disorders: a meta-analysis.” International journal of pediatric otorhinolaryngology (2026). PMID: 42302637 ↗
L1SR_OBSCited in: 12. Special Populations & Pregnancy
[282]
Zhang J, Zhang Y, Li H. “Risk factors for residual obstructive sleep apnea after adenotonsillectomy in children: A single-center retrospective cohort study.” American journal of otolaryngology (2026). PMID: 42349273 ↗
L3COHORTCited in: 12. Special Populations & Pregnancy, 13. Prevention, Screening & Surveillance
[283]
Cano-Valls A, Martinez Monblan MA, Carro-Fernández E et al.. “NURSE-Led Care in Patients Undergoing Catheter Ablation for Atrial Fibrillation: The NURSECAT-AF Randomized Trial.” Circulation. Arrhythmia and electrophysiology (2026). PMID: 41744095 ↗
L1RCTCited in: 13. Prevention, Screening & Surveillance
[284]
Ward SA, Storey E, Naughton MT et al.. “Obstructive sleep apnea and cerebral small vessel disease in community-based older people: an aspirin in reducing events in the elderly imaging substudy.” Sleep (2025). PMID: 39301859 ↗
L2RCTCited in: 13. Prevention, Screening & Surveillance
[285]
Mauries S, Rolland B, Mallevays M et al.. “Conditions of sleep restoration after smoking cessation: A systematic review.” Sleep medicine reviews (2024). PMID: 39893864 ↗
L5SR_OBSCited in: 13. Prevention, Screening & Surveillance
[286]
Adal O, Mamo ST, Belay AE et al.. “The prevalence of asthma and its predictor among patients presetting in Ethiopian public hospitals: systematic review and meta-analysis, 2024.” Therapeutic advances in respiratory disease (2024). PMID: 39235440 ↗
L1SR_OBSCited in: 13. Prevention, Screening & Surveillance
[287]
Garabedian C, Sénat MV, Sananès N et al.. “[Preexisting diabetes: Expert consensus from the College of French Gynecologists and Obstetricians and from the French Society of Diabetology].” Gynecologie, obstetrique, fertilite & senologie (2025). PMID: 41365423 ↗
L1GUIDELINECited in: 13. Prevention, Screening & Surveillance
[288]
Cho J, Kim JH, Kim YH et al.. “Obstructive Sleep Apnea Screening and Effects of Surgery in Acromegaly: A Prospective Study.” Endocrinology and metabolism (Seoul, Korea) (2024). PMID: 38918903 ↗
L2COHORTCited in: 13. Prevention, Screening & Surveillance
[289]
Strausz S, Agafonova E, Tiullinen V et al.. “Genetic Analysis of Obstructive Sleep Apnea and Its Relationship with Severe COVID-19.” Annals of the American Thoracic Society (2024). PMID: 38330144 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[290]
Donovan LM, Wai T, Spece LJ et al.. “Sleep Testing and Mortality in a Propensity-matched Cohort of Patients with Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2023). PMID: 37579136 ↗
L3OTHERCited in: 13. Prevention, Screening & Surveillance
[291]
. “[Guidelines for the diagnosis and treatment of obstructive sleep apnea in adults (2025)].” Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases (2026). PMID: 41820035 ↗
L1GUIDELINECited in: 13. Prevention, Screening & Surveillance
[292]
Cheung E, Shang Y, Kong L et al.. “Performance of obstructive sleep apnea screening questionnaires in hospitalized patients with heart failure.” Sleep medicine (2026). PMID: 42413232 ↗
L4OTHERCited in: 13. Prevention, Screening & Surveillance

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

1. Definition, Classification and Nomenclature

Also Called / Synonyms

Classification of Types and Variants

Severity Classification

Clinical Significance

2. Pathophysiology and Mechanism

3. Epidemiology, Etiology and Risk Factors

Demographic and temporal patterns

Risk factors

Special populations

4. Clinical Presentation

Presenting Symptoms

Physical Examination Findings

Phenotypic Variants

Red Flags

Atypical Presentations

5. Diagnosis and Workup

Home Sleep Apnea Testing (HSAT)

Split-Night Polysomnography

Night-to-Night Variability and Multinight Monitoring

Screening Tools

Biomarkers

Diagnostic Algorithm

6. Severity, Staging and Risk Stratification

Hypoxic Burden and Nocturnal Hypoxemia

Endotypic Traits

Comorbidity‑Anchored Risk Stratification

Polysomnographic Phenotypes

Controversies and Guideline Disagreement

7. Acute Management and Exacerbation Rescue

Step 1: Initial Assessment and Severity Classification

Step 2: Oxygen and Ventilatory Support

Step 3: Pharmacologic Adjuncts

Step 4: Monitoring and Titration

Step 5: Transition to Long-term Management

Drug / Modality Comparison Table

8. Long-term and Definitive Management

Step 1: Selecting First-Line Therapy

Step 2: Initiating and Optimizing PAP

Step 3: Alternative and Adjunctive Therapies

Step 4: Monitoring and Long-term Follow-up

What NOT to Do

Controversies and Guideline Disagreement

Management Algorithm

History and Evolution of Treatment

CPAP: The Gold Standard Established and Refined

Pharmacotherapy: From Abandoned Agents to Noradrenergic Targets

Surgical and Neuromodulatory Advances

Abandoned Approaches: Lessons from Negative Trials

9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)

Long-Term Oxygen Therapy and Home Ventilatory Support

Pulmonary Rehabilitation

Interventional Pulmonology and Advanced Procedures

Perioperative Risk Mitigation in OSA

10. Complications

Respiratory Monitoring and Failure

Autonomic and Cardiovascular Complications

DVT/PE Prophylaxis and Pain Management

Hospital-Acquired Complications

Complication Table

11. Prognosis and Natural History

Untreated Trajectory

Treated Outcomes

Factors That Bend the Curve

12. Special Populations and Pregnancy

Pediatrics

Pregnancy

Elderly

Immunocompromised

Peri-operative

13. Prevention, Screening & Surveillance

Primary Prevention

DVT/PE Prophylaxis and Pain